health
Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001
Directorate: Access to Affordable Medicines
Tel: (012) 395 8130 Fax: (012) 395 8823/4

Enquiries: CPA Ref: HP06-2021SVP e-mail: cpapharma@health.gov.za

CONTRACT NUMBER HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD OF 01 MAY 2021 TO 30 APRIL 2024

ADDENDUM 1: REPLACEMENT OF VERSION 1 CONTRACT CIRCULAR

Please note that awards for Safeline Pharmaceuticals (Pty) Ltd and Fresenius Kabi South Africa (Pty) Ltd has been processed and included in this contract circular.

Kindy replace version 1 of the Contract Circular of HP06-2021SVP with version 2, attached as Annexure A to this addendum.

Yours faithfully

K JAMALOODIEN
DIRECTOR: AFFORDABLE MEDICINES
DATE: 15 April 2021

health
Department:
Health
REPUBLIC OF SOUTH AFRICA

Private Bag X828, PRETORIA, 0001. Civitas Building Cnr Thabo Sehume & Struben Streets, PRETORIA 0001
Directorate: Affordable Medicines, Tel: (012) 395 8530 Fax: (012) 395 8823/4

Enquiries: tenders@health.gov.za Ref: **HP06-2021SVP**

HP06-2021SVP: SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024

1. The attached contract circular is for your information.

2. This contract will be subject to the General Conditions of Contract issued in accordance with Chapter 16A of the Treasury Regulations published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Requirements and Conditions of Contract are supplementary to the General Conditions of Contract. Where, however, the Special Requirements and Conditions of Contract are in conflict with the General Conditions of the Contract, the Special Requirements and Conditions of Contract will prevail.

3. The bid price offered applies to the product specified e.g. price per single unit, as per specification.

4. The following provincial Departments of Health will participate in this contract:

PARTICIPANTS	CONTACT PERSON	TEL NO	E-MAIL
Eastern Cape	Mr C Dlova	(047) 532-5536	mncedisi.dlova@echealth.gov.za
Free State	Ms M Smits	(051) 411-0525	SmitsM1@fshealth.gov.za
Gauteng	Mr DS Malele	(011) 628-9131	dumisane.malele@gauteng.gov.za
Kwazulu-Natal	MS SB Nhlapo	(035) 901-7004	sibusisiwe.nhlapo@kznhealth.gov.za
Limpopo	Mr TS Rasekele	(015) 223-9065	rassolly@gmail.com
Mpumalanga	Mr T Moralo	(013) 283-9001	tshegofatsom@mpuhealth.gov.za
North West	Mr M Gutta	(018) 384-4838	mgutta@nwpg.gov.za
Northern Cape	Ms E Delport	(053) 830-2717	edelport@ncpg.gov.za
Western Cape	Mr N Mia	(021) 483-5800	nisaar.mia@westerncape.gov.za

K JAMALOODIEN
DIRECTOR: AFFORDABLE MEDICINES
For: DIRECTOR-GENERAL: HEALTH
DATE: 15 April 2021

1. IMPORTANT GENERAL INFORMATION

1.1 Please note that two supplier codes are listed for each supplier. This is to provide for the required supplier registration on the Central Supplier Database (CSD) at National Treasury.

1.2 Please note that the delivered price is for the unit of measure (UOM) offered. Unit of Measure, National Stock Numbers and prices should be carefully matched when placing or executing orders.

1.3 All prices are inclusive of 15 % VAT.

1.4 All prices are on a delivered basis.

1.5 Contact persons and e-mail addresses indicated hereunder are to be used for contract enquiries and not for orders.

2. NAMES AND ADDRESSES OF CONTRACTORS AND CONTACT DETAIL

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Abbott Laboratories South Africa (Pty) Ltd	V2150	MAAA0030395	219 Golf Club Terrace **CONSTANTIA KLOOF** 1709	Maxine Smith	(011) 858-2379 (060) 579-7944	maxine.smith@abbott.com
AbbVie (Pty) Ltd	V3PG3	MAAA0076921	P O Box 4840 **WELTEVREDEN PARK** 1709	Sarona Radley	(011) 831-3200 (060) 348-9941	sarona.radley@abbvie.com
Accord Healthcare (Pty) Ltd	V2MB8	MAAA0005335	Private Bag X51 **RIVONIA** 2128	Reslan Nagoor	(011) 234-5703 (082) 494-2510	reshlan.nagoor@accordhealth.co.za
Actor Pharma (Pty) Ltd	V2G28	MAAA0183044	P O Box 7408 **HALFWAY HOUSE** 1685	Malcolm Blane s	(011) 312-3812 (082) 551-4010	malcolmb@actorpharma.co.za
Adcock Ingram Critical Care (Pty) Ltd	V4222	MAAA0010153	P O Box 6888 **JOHANNESBURG** 2000	Vusani Matshidza	(011) 494-8129 (079) 894-7873	criticalcare.tenders@adcock.com

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Adcock Ingram Healthcare (Pty) Ltd	V2272	MAAA0036413	Private Bag X69 **BRYANSTON** 2021	Nkosinathi.Mthethwa	(011) 635-0103 (072) 328-1179	nkosinathi.mthethwa@adcock.com
Ascendis Pharma (Pty) Ltd	V0DM6	MAAA0043637	Postnet Suite #252 Private Bag X21 **BRYANSTON** 2021	Marnus Sonnekus	(011) 036-9600 (082) 329-8225	marnus.sonnekus@ascendishealth.com
B Braun Medical (Pty) Ltd	VYL89	MAAA0040832	P O Box 1787 **RANDBURG** 2125	Walda Van Zyl	(010) 222-3000 (073) 494-8695	walda.van_zyl@bbraun.com
Biotech Laboratories (Pty) Ltd	VUV35	MAAA0029826	Private Bag X65 **HALFWAY HOUSE** 1685	Faried Dean	(011) 848-3050 (082) 455-1149	tenders@biotechlabs.co.za
Equity Pharmaceuticals (Pty) Ltd	V1QZ3	MAAA0007480	100 Sovereign Drive Route 21, Corporate Park Nelmapius Drive **IRENE** 0157	Carel Bouwer	(012) 345-1747 (082) 879-8866	carel@equitypharma.co.za
Ferring (Pty) Ltd	VXY92	MAAA0005879	Route 21, Corporate Park 6 Regency Drive **IRENE** 0157	Martha van Zyl	(012) 443-4307 (082) 565-2656	mvz@ferring.com mercia.vanzyl@ferring.com
Fresenius Kabi SA (Pty) Ltd	VAJL3	MAAA0007374	P O Box 4156 **HALFWAY HOUSE** 1685	Jeannine Terblanche	(011) 545 0000	Jeannine.Terblanche@fresenius-kabi.com
Lundbeck SA (Pty) Ltd	VVS90	MAAA0031052	P O Box 2171 **NORTHRIDING** 2162	Julianne Howarth	(011) 699-1600 (078) 800-3843	jhll@lundbeck.com
Litha Pharma (Pty) Ltd (Acino Pharma)	VGS73	MAAA0009244	P O Box 8356 **MIDRAND** 1685	Anand Reddy	(011) 516-1700 (066) 304-6900	state_za@acino.swiss

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Macleods Pharmaceuticals SA (Pty) Ltd	V3PJ1	MAAA0007167	Office Block 1, Bassonia Estate Office Park (East) 1 Cussonia Drive Bassonia Rock Ext 12 **ALBERTON** 2061	Vanita Rajool	(011) 628-1169 (083) 266-9223	vanitar@macleodspharma.com
Mylan (Pty) Ltd	V3PS6	MAAA0081441	Postnet Suite X23 Private Bag X10010 **EDENVALE** 1610	Kumaraswamy Ekhambaram	(011) 451-1300 (071) 473-3900	kumaraswamy.ekhambaram@mylan.in
Novartis SA (Pty) Ltd	VBVW2	MAAA0006317	Magula Cresent West, Waterfall City Lukskei Vlei **MIDRAND** 2090	Masego Masipa	(011) 347-6600 (082) 805-1262	masego.masipa@novartis.com
Novo Nordisk (Pty) Ltd	V2743	MAAA0013414	P O Box 783155 **SANDTON** 2146	Venkata Kalyan Papa Konduri	(011) 202-0500 (079) 694-1953	tsmk@novonordisk.com
P & G South African Trading (Pty) Ltd	VJDY7	MAAA0913191	Private Bag X10062 **SANDTON** 2196	Deon Labuschagne	(010) 001-9650 (082) 897-3611	labuschagne.d@pg.com
Pfizer Laboratories (Pty) Ltd	V2189	MAAA0019202	85 Bute Lane **SANDTON** 2146	Themba Mnguni	(011) 320-6091 (082) 307-9658	themba.mnguni@pfizer.com
Pharmacare Limited	V2205	MAAA0008452	P O Box 1587 **GALLO MANOR** 2052	Itumeleng Mathe	(011) 239-6243 (083) 298-4366	imathe@aspenpharma.com

Supplier Name	Supplier Code	CSD Code	Postal Address	Contact Person	Telephone / Cellphone Number	E-mail
Pharmaco Distribution (Pty) Ltd	VBVW1	MAAA0044115	P O Box 786522 **SANDTON** 2146	Jan van den Berg	(011) 784-0077 (082) 572-7832	jan.vandenberg@pharmaco.co.za
Pharma-Q (Pty) Ltd	V1NK1	MAAA0016762	Private Bag X09 **FLORIDA** 1710	Anand Mehta	(011) 247-1600 (083) 636-4444	andy@pharmaq.co.za
Piramal Critical Care SA (Pty) Ltd	VFPD3	MAAA0655823	P O Box 1088 **CRESTA** 2188	Divya Ranchod	(011) 678-1948 (082) 454-1781	divya.ranchod@piramal.com
Ranbaxy Pharmaceuticals (Pty) Ltd	V4728	MAAA0000384	P O Box 43486 **INDUSTRIA** 2042	Deepakh Sewnarain	(012) 643-2000 (082) 893-8649	deepakh.sewnarain@sunpharma.com
Safeline Pharmaceuticals (Pty) Ltd	VZL63	MAAA0002530	P O Box 7900 **PALMCOURT** 1709	Kay Naidu	(011) 288-5360 (082) 459-2709	kayn@safeline.co.za
Sandoz SA (Pty) Ltd	VVZ69	MAAA0011663	P O Box 12257 **VORNA VALLEY** 1686	Renee Moodley	(011) 545-0424 (083) 704-1806	renee.moodley@sandoz.com
Sanofi-Aventis SA (Pty) Ltd	V2160	MAAA0009069	Private Bag X207 **MIDRAND** 1685	Jaidev Maharaj	(011) 847-5264 (082) 943-3952	jaidev.maharaj@sanofi.com
Specpharm (Pty) Ltd	V3EQ1	MAAA0009737	P O Box 651 **HALFWAY HOUSE** 1685	Gregory Hill	(011) 652-0465 (073) 676-0775	ghill@specpharm.co.za
Unimed Healthcare (Pty) Ltd	V92D6	MAAA0444639	Private Bag X12 **PRETORIA WEST** 0117	Arshad Bera	(011) 056- 6999 (083) 647-7860	arshad@unimedhealthcare.co.za

Item No	Item Specification	*ADD	Estimate	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
1	Acetylcysteine 200mg/ml, injection, 10ml			213 295		Equity Pharmaceuticals (Pty) Ltd	MAAA0007480	V1QZ3	Paradote	R196.00	1 x 10 vials	14	1 x 10 vials	91.00	181915188	VI
2	Adenosine 3mg/ml, injection, 2ml			74 740		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	ADENOCOR VIALS 6MG / 2ML 6	R156.21	1 x 1	14	6	91.00	180373081	VI
3	Adrenaline (Epinephrine) 0.15mg/0.3ml, auto-injection, 0.3ml			5 570		Mylan (Pty) Ltd	MAAA0081441	V3PS6	EPIPEN JUNOR AUTO-INJECTOR	R760.00	1 x 1	14	10	93.00	222000173	EA
4	Adrenaline (Epinephrine) 0.3mg/0.3ml, auto-injection, 0.3ml			2 336		Mylan (Pty) Ltd	MAAA0081441	V3PS6	EPIPEN	R749.00	1 x 1	14	10	93.00	222000174	EA
5	Adrenaline (Epinephrine) 1mg/ml, injection, 1ml		7 520 710	6 768 639	90%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Adrenaline Inj 1mg/1ml	R4.00	1 x 10	14	500	96.00	180075485	AM
5	Adrenaline (Epinephrine) 1mg/ml, injection, 1ml **Product awarded:** **Adrenaline (Epinephrine) 1mg/ml, injection, 1ml** **Remaining shelf life: 4 - 10 months**	**1**		752 071	10%	Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	ADRENALINE FRESENIUS 1 mg/1 ml (1:1000)	R4.84	1 x 1	14	10 Amps	72.10	180075485	AM
6	Alfentanil 0.5mg/ml, injection, 2ml			119 310		Piramal Critical Care SA (Pty) Ltd	MAAA0655823	VFPD3	Rapifen 2ml	R49.83	5 x 2ml amps	14	5 x 2ml amps	90.00	180075489	AM
7	Alprostadil 0.5mg/ml, injection, 1ml **Product awarded:** **Alprostadil 0.5mg/ml, injection, 1ml** **1 pack of 5 injections** **Price vs Pack size:** **1 x 1 injection = R2,744.60** **1 x 5 injections = R13,723.09**			6 250		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	PROSTIN VR	R2 744.60	1 x 5	14	5	91.00	180075498	AM
9	Aminophylline 25mg/ml, injection, 10ml			354 560		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	Sabax Aminophylline IV	R3.57	1 x 10 vials	14	10	99.87	189700102	AM
10	Amiodarone 50mg/ml, injection, 3ml			223 660		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	CORDARONE X IV 150MG/3ML 6	R61.09	1 x 1	14	6	91.00	180075509	AM
11	Atracurium 10mg/ml, injection, 2.5ml			81 270		Pharmacare Limited	MAAA0008452	V2205	Tracrium Inj 5x2.5ml	R78.66	5 x 2.5ml	14	5	95.00	180075518	AM
12	Atracurium 10mg/ml, injection, 5ml			58 400		Pharmacare Limited	MAAA0008452	V2205	Tracrium Inj 5x5ml	R158.41	5 x 5ml	14	5	95.00	180075520	AM
13	Atropine 0.5mg/ml, injection, 1ml		1 278 840	1 023 072	80%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Atropine Inj. 0,5mg/1ml	R4.00	1 x 10	14	500	96.00	189707023	AM
13	Atropine 0.5mg/ml, injection, 1ml	**1**	1 278 840	255 768	20%	Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	ATROPINE SULPHATE FRESENIUS 0.5 mg/1 ml	R4.43	1 x 1	14	10 Amps	81.33		
14	Atropine 1mg injection, 1ml		2 353 110	1 882 488	80%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Atropine Inj. 1mg/1ml	R4.20	1 x 10	14	400	96.00	189707024	AM
14	Atropine 1mg injection, 1ml	**1**	2 353 110	470 622	20%	Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	ATROPINE SULPHATE FRESENIUS 1.0 mg/1 ml	R4.78	1 x 1	14	10 Amps	78.57		
15	Betamethasone 4mg/ml, injection, 1ml			1 199 860		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Betamethasone 4mg/1ml	R4.75	1 x 10	14	400	96.00	180075545	AM
16	Biperiden 5mg, injection, 1ml			63 180		Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	AKINETON	R45.17	1 x 5	14	5	90.00	180075548	AM
17	Bupivacaine 5mg, Adrenaline 5mcg/ml, injection, 20ml			292 780		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	MACAINE HCL 0,5% INJECTION WITH ADRENALINE	R31.05	1 x 10 vials	14	10	100.00	180075555	AM
18	Bupivacaine 5mg, Dextrose Anhydrous 72.7mg/ml, injection, 4ml			974 370		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	MACAINE HCL 0.5% SPINAL INJECTION WITH DEXTROSE	R4.60	1 x 10	14	10	100.00	180075556	AM
19	Bupivacaine 5mg/ml injection, spinal, 4ml			206 140		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	MACAINE HCL 0.5% SPINAL INJECTION	R16.68	1 x 10	14	10	100.00	180075553	AM

Item No	Item Specification	*ADD	Estimate	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
20	Bupivacaine 5mg/ml, injection, 10ml			971 660		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	MACAINE HCL 0.5% INJECTION	R6.90	1 x 10	14	10	100.00	180075551	AM
21	Caffeine 20mg/ml, injection, 1ml	1		185 250		Safeline Pharmaceuticals (Pty) Ltd	MAAA0002530	VZL63	CAYONA 20mg/ml	R380.73	1 x 1	14	100	92.00	222001198	EA
22	Calcium gluconate 10% m/v, injection, 10ml	1		754 340		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	CALCIUM GLUGONATE FRESENIUS	R12.65	1 x 1	14	10 Amps	91.00	180075565	AM
23	Cisatracurium 2mg/ml, injection, 2.5 ml		266 650	239 985	90%	Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Cistrax 5mg/2.5ml	R25.30	1 x 5	14	20	91.00	181767288	AM
23	Cisatracurium 2mg/ml, injection, 2.5 ml		266 650	26 665	10%	**TO FOLLOW**										
24	Cisatracurium 2mg/ml, injection, 5ml		237 390	166 173	70%	Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Cistrax 10mg/5ml	R37.95	1 x 5	14	20	91.00	180308024	AM
24	Cisatracurium 2mg/ml, injection, 5ml		237 390	71 217	30%	**TO FOLLOW**										
26	Clotiapine 10mg/ml, injection, 4ml			78 395		Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	ETOMINE	R28.72	1 x 10	14	10	90.00	180075729	AM
29	Desmopressin 4mcg, injection, 1ml			9 660		Ferring (Pty) Ltd	MAAA0005879	VXY92	DDAVP INJECTION 4MCG/ML 1ML	R97.95	1 x 10 ampoules per pack	14	5 x 10 ampoules pack (50 ampoules)	90.00	180075757	AM
30	Dexamethasone 4mg, injection, 1ml		5 270 300	4 743 270	90%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Dexamethasone Phosphate Inj. 4mg/1ml	R5.40	1 x 10	14	400	96.00	180075759	AM
30	Dexamethasone 4mg, injection, 1ml	1	5 270 300	527 030	10%	Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	FRESENIUS DEXAMETHASONE 4 mg/1 ml	R8.70	1 x 1	14	10 Amps	36.00		
31	Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml **Product awarded:** **Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml** **1 pack of 5 injections** **Price vs Pack size:** **1 x 1 injection = R510.82** **1 x 5 injections = R2,554.10**			58 320		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	PreceDEX	R510.82	1 x 5	14	5	91.00	181937349	AM
32	Dextrose 50% m/v, injection, 20ml	1		1 293 980		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	DEXTROSE FRESENIUS 50 % (20 ml) INJECTION	R19.81	1 x 1	14	10 Amps	91.00	180075794	AM
33	Dextrose 50% m/v, injection, 50ml	1		1 140 740		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	DEXTROSE-FRESENIUS 50% (50ml)	R28.55	1 x 1	14	60 Bags	91.00	180352804	BG
34	Diazepam 5mg/ml, injection, 2ml			771 330		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Diazepam Inj. 10mg/2ml	R4.00	1 x 10	14	400	96.00	180075798	AM
35	Diclofenac 25mg/ml, injection, 3ml		8 327 390	6 661 912	80%	Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	Diclofenac Injection Unimed	R1.52	1 x 50	14	750	100.00	180075799	AM
				1 665 478	20%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Dicon 75 inj	R1.65	1 x 50	14	500	88.30		
36	Digoxin 0,25mg/ml, injection, 2ml			39 280		Pharmacare Limited	MAAA0008452	V2205	Lanoxin 0.5mg Inj 5 x 2ml	R21.39	5 x 2ml	14	5	95.00	180075803	AM
38	Dobutamine 12.5mg/ml, injection, 20ml	1		206 440		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	DOBUTAMINE FRESENIUS 250 mg/20 ml	R75.44	1 x 1	14	5 Amps	91.00	189715235	VI
39	Dopamine 40mg/ml, injection, 5ml			106 755		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Dopamine Concentrate Inj. 200mg/5ml	R7.80	1 x 10	14	250	96.00	180075879	AM
40	Enoxaparin 40mg, injection, 0.4ml			8 663 680		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	CLEXANE PF SYRINGE 40mg 10 X 0.4ML	R53.61	1 x 1	14	10	91.00	180077964	SG
41	Enoxaparin 60mg, injection, 0.6ml			901 800		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	CLEXANE PF SYRINGE 60mg 10 X 0.6ML	R67.49	1 x 1	14	10	91.00	222000901	SG

Item No	Item Specification	*ADD	Estimate	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
42	Enoxaparin 80mg, injection, 0.8ml			2 019 230		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	CLEXANE PF SYRINGE 80mg 10 X 0.8ML	R81.50	1 x 1	14	10	91.00	180970533	EA
50	Etomidate 2mg/ml, injection, 10ml			145 080		Piramal Critical Care SA (Pty) Ltd	MAAA0655823	VFPD3	Hypnomidate	R36.74	5 x 10ml amps	14	5 x 10ml amps	90.00	180075956	AM
51	Fentanyl 0.05mg/ml, injection, 2ml		1 581 570	1 423 413	90%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Fentanyl Inj. 100ug/2ml	R4.70	1 x 10	14	400	96.00	180075959	AM
51	Fentanyl 0.05mg/ml, injection, 2ml **Product awarded:** **Fentanyl 0.05mg/ml, injection, 2ml** **1 pack of 10 injections** **Price vs Pack size:** **1 x 1 injection = R7.22** **1 x 10 injections = R72.20**	**1**		158 157	10%	Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	FENTANYL FRESENIUS 100 mcg/2 ml	R7.22	1 x 10	14	10 Amps	42.74	180075959	AM
52	Fentanyl 0.05mg/ml, injection, 10ml			370 850		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Fentanyl Inj. 500ug/10ml	R10.20	1 x 10	14	200	96.00	180075960	AM
54	Flupenthixol decanoate 20mg/ml, injection, 1ml			1 507 530		Lundbeck SA (Pty) Ltd	MAAA0031052	VVS90	Fluanxol Depot 20 mg/ml	R36.06	1 x 1	14	5	90.00	180017761	AM
55	Furosemide 10mg/ml, injection, 25ml	**1**		245 280		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	FRUSEMIDE FRESENIUS 250 mg/25 ml	R23.92	1 x 1	14	10 Amps	91.00	180075988	AM
56	Furosemide 10mg/ml, injection, 2ml			7 085 900		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	ADCO FUROSEMIDE 20MG/2ML	R2.97	1 x 10 vials	14	10	100.00	180075982	AM
57	Furosemide 10mg/ml, injection, 5ml			342 230		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Furosemide Inj. 50mg/5ml	R5.55	1 x 10	14	300	96.00	180075985	AM
58	Glucagon 1mg, injection, 1ml			30 050		Novo Nordisk (Pty) Ltd	MAAA0013414	V2743	GLUCAGEN HYPOKIT	R394.98	1 x 1	14	1	92.00	180309135	VI
60	Glycopyrronium bromide 0.2mg/ml, injection, 2ml			622 200		Pharmacare Limited	MAAA0008452	V2205	Robinul Inj 2ml	R12.84	10 x 2ml	14	10	95.00	180075998	AM
65	Hydrocortisone 100mg/2ml, injection, 2ml		4 166 740	3 750 066	90%	Macleods Pharmaceuticals SA (Pty) Ltd	MAAA0007167	V3PJ1	Macleods Hydrocortisone Injection	R17.37	1 x 2ml	14	100	95.00	180018040	VI
65	Hydrocortisone 100mg/2ml, injection, 2ml **Product awarded:** **Hydrocortisone 100mg/2ml, injection, 2ml** **1 pack of 5 injections** **Price vs Pack size:** **1 x 1 injection = R39.34** **1 x 5 injections = R196.70**		4 166 740	416 674	10%	Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	SOLU-CORTEF 100mg	R39.34	1 x 5	14	5	-22.83	180018040	VI
66	Hyoscine Butylbromide 20mg, injection, 1ml			2 338 110		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Hyoscine Butylbromide Inj. 20mg/1ml	R5.30	1 x 10	14	300	96.00	180076081	AM
67	Insulin analogue, Human, Long-acting, 100 u/ml, disposable pen, 3ml			33 860		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	OPTISULIN SOLOSTAR 3ML 5	R51.06	1 x 1	14	5	91.00	222000179	EA
68	Insulin analogue, Human, Ultrafast-acting 100 u/ml, disposable pen, 3ml			229 559		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	APIDRA SOLOSTAR 100IU/ML 3 ML 5	R72.68	1 x 1	14	5	91.00	222000181	EA
69	Insulin analogue, Human, Ultrafast-acting 100 u/ml, vial, 10ml			1 540		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	APIDRA VIALS 10ML 1	R244.95	1 x 1	14	10	91.00	222000182	VI
70	Insulin, Biosynthetic, Human, Isophane, 100 u/ml, disposable pen, 3ml			2 832 200		Novo Nordisk (Pty) Ltd	MAAA0013414	V2743	PROTAPHANE HM	R32.06	1 x 5	14	10	92.00	180309126	SG
71	Insulin, Biosynthetic, Human, Isophane, 100 u/ml, vial, 10ml			903 640		Novo Nordisk (Pty) Ltd	MAAA0013414	V2743	PROTAPHANE HM	R34.14	1 x 1	14	10	92.00	189710587	VI

Item No	Item Specification	*ADD	Estimate	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
72	Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, disposable pen, 3ml			13 676 740		Novo Nordisk (Pty) Ltd	MAAA0013414	V2743	ACTRAPHANE HM	R30.37	1 x 5	14	10	92.00	180309129	SG
74	Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, vial, 10ml			4 520 360		Novo Nordisk (Pty) Ltd	MAAA0013414	V2743	ACTRAPHANE HM	R34.14	1 x 1	14	10	92.00	189711634	VI
75	Insulin, Biosynthetic, Human, Soluble, 100 u/ml, disposable pen, 3ml			1 886 440		Novo Nordisk (Pty) Ltd	MAAA0013414	V2743	ACTRAPID HM	R32.06	1 x 5	14	10	92.00	180309128	SG
76	Insulin, Biosynthetic, Human, Soluble, 100 u/ml, vial, 10ml			387 840		Novo Nordisk (Pty) Ltd	MAAA0013414	V2743	ACTRAPID HM	R34.14	1 x 1	14	10	92.00	189710585	VI
77	Iron dextran containing elemental iron 50mg/ml, injection, 10ml			16 500		Litha Pharma (Pty) Ltd (Acino Pharma)	MAAA0009244	VGS73	COSMOFER	R310.13	1 x 2	14	1 x 2	100.00	181871852	AM
78	Iron dextran containing elemental iron 50mg/ml, injection, 2ml			211 350		Litha Pharma (Pty) Ltd (Acino Pharma)	MAAA0009244	VGS73	COSMOFER	R62.03	1 x 5	14	1 x 5	100.00	181891028	AM
79	Iron sucrose containing elemental iron 20mg/ml, injection, 5ml			271 550		Actor Pharma (Pty) Ltd	MAAA0183044	V2G28	Rautevene	R48.53	5 x 5ml ampules	14	50	90.00	180185678	AM
80	Isulin analogue, Human, Ultrafast-acting 100 u/ml, penfill cartridge for use in pens, 3ml **(PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)**			7 725		Sanofi-Aventis SA (Pty) Ltd	MAAA0009069	V2160	APIDRA 300IU CART 5	R69.46	1 x 1	14	5	91.00	222000180	EA
81	Ketamine 10mg/ml, injection, 20ml	**1**		96 930		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	KETAMINE FRESENIUS 10 mg/1 ml	R37.03	1 x 1	14	10 Vials	91.00	189710933	VI
82	Ketamine 100mg/ml, injection, 10ml	**1**		61 060		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	KETAMINE FRESENIUS 100 mg/1 ml	R98.39	1 x 1	14	10 Vials	91.00	189706747	VI
83	Ketamine 50mg/ml, injection, 10ml	**1**		87 050		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	KETAMINE FRESENIUS 50 mg/1 ml	R49.20	1 x 1	14	10 Vials	91.00	189710574	VI
85	Lidocaine 1% m/v, injection, not for iv use, 20ml			1 821 100		B Braun Medical (Pty) Ltd	MAAA0040832	VYL89	Lignocaine-HCL B.Braun 1% 20ml (Product Code: 3659091)	R8.38	1 x 1	14	20	96.00	180076306	VI
86	Lidocaine 10% m/v, iv injection, 5ml	**1**		39 220		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	LIGNOCAINE HCl FRESENIUS 10% (AMPOULES)	R12.07	1 x 1	14	10 Amps	91.00	180076360	AM
87	Lidocaine 2% m/v injection, not for iv use, 20ml			1 191 930		B Braun Medical (Pty) Ltd	MAAA0040832	VYL89	Lignocaine-HCL B.Braun 2% 20ml (Product Code: 3659089)	R8.67	1 x 1	14	20	96.00	189703157	VI
88	Lidocaine 2% m/v, Adrenaline 12.5mcg (1:80 000), dental cartridge, 1.8ml			18 119 370		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Xylotox E80-A	6.79	100 x 1.8ml box	14	1 x 100 x 1.8ml	100.00	180076312	CA
89	Lidocaine 2% m/v, dental cartridge, 1.8ml			2 814 860		Adcock Ingram Healthcare (Pty) Ltd	MAAA0036413	V2272	Xylotox S.E. Plain	6.79	100 x 1.8ml box	14	1 x 100 x 1.8ml	99.93	180076343	CA
90	Lidocaine 2% m/v, iv injection, 5ml			1 964 420		B Braun Medical (Pty) Ltd	MAAA0040832	VYL89	Lignocaine-HCL B. Braun 2% 5ml (Product Code: 3659970)	R2.89	1 x 1	14	20	96.00	180076308	AM
92	Magnesium sulfate 50%, injection, 2ml			5 111 040		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	SABAX MAGNESIUM SULPHATE 50%	R3.45	1 x 10 vials	14	10	100.00	189710942	AM
93	Mannitol 25% m/v, injection, 50ml **Product awarded:** **Mannitol 25% m/v, injection, 50ml** **1 pack of 60 bags** **Remaining shelf life: 4 - 10 months** **Price vs Pack size:** **1 x 1 bag = R49.51** **1 x 60 bags = R2,970.60**	**1**		19 320		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	MANNITOL FRESENIUS 25 % INJECTION	R49.51	1 x 1	14	60 Bags	91.00	189704505	AM
96	Methylprednisolone 500mg, (as sodium succinate) injection, 8ml			100 830		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	SOLU-MEDROL 500mg	R159.91	1 x 1	14	1	91.00	189710955	VI
97	Methylprednisolone acetate 40mg/ml, injection, 2ml			257 150		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	DEPO-MEDROL 40 mg	R34.88	1 x 1	14	1	91.00	189710776	VI

Item No	Item Specification	*ADD	Estimate	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
98	Methylprednisolone acetate 40mg/ml, injection, 5ml			18 412		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	DEPO-MEDROL 40 mg	R97.18	1 x 1	14	1	91.00	189710775	VI
99	Metoclopramide 5mg/ml, injection, 2ml		7 601 990	760 199	10%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Metoclopramide Inj 10mg/2ml	R3.45	1 x 10	14	400	44.86	180076396	AM
				6 841 791	90%	**TO FOLLOW**									180076396	AM
100	Midazolam 1mg/ml, injection, 5ml		595 200	357 120	60%	Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	ADCO MIDAZOLAM INJECTION 5MG/5ML	R6.21	1 x 10	14	10	92.80	180076401	AM
				238 080	40%	Accord Healthcare (Pty) Ltd	MAAA0005335	V2MB8	Accord Midazolam 5 mg/5 ml	R5.75	1 x 10	14	20	91.00		
101	Midazolam 5mg/ml, injection, 10ml			127 300		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Midazolam Inj. 50mg/10ml	R19.25	1 x 10	14	100	96.00	180018352	AM
102	Midazolam 5mg/ml, injection, 3ml		948 930	569 358	60%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Midazolam Inj. 15mg/3ml	R7.50	1 x 5	14	300	96.00	180076404	AM
102	Midazolam 5mg/ml, injection, 3ml **Product awarded:** **Midazolam 5mg/ml, injection, 3ml** **1 pack of 10 injections** **Price vs Pack size:** **1 x 1 injection = R8.17** **1 x 10 injections = R81.70**		948 930	379 572	40%	Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	ADCO MIDAZOLAM INJECTION 15MG/3ML	R8.17	1 x 10	14	10	91.96	180076404	AM
103	Morphine 10mg/ml, injection, 1ml		3 307 110	2 976 399	90%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Morphine Inj. 10mg/1ml	R3.90	1 x 10	14	300	96.00	189703413	AM
		1		330 711	10%	Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	MORPHINE SULPHATE FRESENIUS PF 10 mg/1 ml	R5.24	1 x 1	14	10 Amps	60.08		
104	Morphine 15mg/ml, injection, 1ml		1 772 750	1 595 475	90%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Morphine Inj. 15mg/1ml	R4.10	1 x 10	14	300	96.00	189700425	AM
		1		177 275	10%	Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	MORPHINE SULPHATE FRESENIUS PF 15 mg/1 ml	R5.35	1 x 1	14	10 Amps	63.56		
105	Naloxone 0.02mg/ml, injection, 2ml	1		96 540		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	NALOXONE HCI NEONATAL FRESENIUS 0.02 mg/1 ml	R9.05	1 x 1	14	10 Amps	91.00	189708068	AM
106	Naloxone 0.4mg/ml, injection, 1ml	1		504 980		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	NALOXONE HCI FRESENIUS 0.4 mg/1 ml	R7.61	1 x 1	14	10 Amps	91.00	189705061	AM
109	Needle, Insulin, 31G x 5mm, sterile, suitable for use with all prefilled insulin injection devices, 100			82 770		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	INSUPEN 31g X 5mm	R60.02	1 x 100	14	36	95.61	181915212	BX
110	Needle, Insulin, 31G x 8mm, sterile, suitable for use with all prefilled insulin injection devices, 100			377 460		Unimed Healthcare (Pty) Ltd	MAAA0444639	V92D6	INSUPEN 31g X 8mm	R56.48	1 x 100	14	36	99.10	181915214	BX
112	Neostigmine 2.5mg, injection, 1ml			481 450		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Neostigmine Methyl Sulphate Inj. 2.5mg/1ml	R6.16	1 x 10	14	200	96.00	180089506	AM
113	Octreotide 0.05mg, injection, 1ml			14 020		Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Sandostatin 0.05mg	R 104.36	1 x 5	14	1	91.00	180076442	AM
114	Octreotide 0.1mg, injection, 1ml			119 395		Novartis SA (Pty) Ltd	MAAA0006317	VBVW2	Sandostatin 0.1mg	R 199.10	1 x 5	14	1	91.00	180076445	AM
116	Oxytocin 10 iu, injection, 1ml		6 406 260	3 203 130	50%	Specpharm (Pty) Ltd	MAAA0009737	V3EQ1	Spec Oxytocin 10iu	R15.25	1 x 10	14	1 pack of 10's	99.00	180076472	AM
117	Oxytocin 5 iu, injection, 1ml		2 063 960	1 031 980	50%	Specpharm (Pty) Ltd	MAAA0009737	V3EQ1	Spec Oxytocin 5iu	R14.77	1 x 10	14	1 pack of 10's	99.00	180076470	AM
118	Oxytocin 5iu, Ergometrine 0.5mg, injection, 1ml			538 290		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	SYNTOMETRINE	R27.85	1 x 5	14	5	100.00	180076474	AM

Item No	Item Specification	*ADD	Estimate	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
119	Pantoprazole 40mg, injection, 10ml			1 042 800		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	PANTOCID 40MG INJECTION 10ML	R22.94	1 x 1	14	10	95.00	181753528	VI
120	Paracetamol 10mg/ml, injection for IV infusion, 100ml			1 585 240		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	PARACETAMOL BIOTECH IV	R11.74	1 x 100ml	14	10	96.00	181818827	VI
122	Pethidine 25mg/ml, injection, 1ml			354 260		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Pethidine Inj. 25mg/1ml	R4.60	1 x 10	14	400	96.00	189703124	AM
123	Pethidine 50mg/ml, injection, 1ml		1 815 320	1 452 256	80%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Pethidine Inj. 50mg/1ml	R4.20	1 x 10	14	400	96.00	180076519	AM
		1		363 064	20%	Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	PETHIDINE HCl FRESENIUS PF 50 mg/1 ml	R4.67	1 x 1	14	10 Amps	80.93		
124	Pethidine 50mg/ml, injection, 2ml		2 769 710	2 492 739	90%	Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Pethidine Inj. 100mg/2ml	R4.90	1 x 10	14	400	96.00	180076540	AM
		1		276 971	10%	Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	PETHIDINE HCl FRESENIUS PF 100 mg/2 ml	R6.21	1 x 1	14	10 Amps	66.94		
125	Phenylephrine 10mg, injection, 1ml **<u>Product awarded:</u>** **Phenylephrine 10mg, injection, 1ml** **1 pack of 5 injections** **Price vs Pack size:** **1 x 1 injection = R67.02** **1 x 5 injections = R335.10**			637 460		Abbott Laboratories South Africa (Pty) Ltd	MAAA0030395	V2150	Phenylephrine 10mg, injection, 1ml	R67.02	1 x 5	14	1 x 5	94.00	180076556	AM
126	Phenytoin 50mg/ml, injection, 5ml			1 278 200		Ascendis Pharma (Pty) Ltd	MAAA0043637	V0DM6	Phlexy 250 mg/5ml	R42.48	1 x 5ml vial	14	10 vials	100.00	189708084	VI
127	Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial			35 215		AbbVie (Pty) Ltd	MAAA0076921	V3PG3	Survanta	R1 631.44	1 x 4ml	14	10	91.00	181772157	VI
128	Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial			17 274		AbbVie (Pty) Ltd	MAAA0076921	V3PG3	Survanta	R3 262.39	1 x 8ml	14	10	91.00	189753628	VI
129	Potassium Chloride 15%, m/v injection, 10ml	**1**		2 470 180		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	POTASSIUM CHLORIDE FRESENIUS 15 % (Flexivial)	R2.13	1 x 1	14	20 Flexivials	91.00	189710612	AM
130	Potassium Phosphate Monobasic, Anhydrous, Potassium Phosphate Dibasic Anhydrous, 1.09g/1.05g, injection, 10ml			131 090		Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	SABAX POTASSIUM PHOSPHATE SOLUTION FOR INJECTION AFTER DILUTION	R60.38	1 x 10	14	10	100.00	180076573	AM
131	Promethazine 25mg/ml, injection, 1ml	**1**		691 430		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	PROMETHAZINE HCl FRESENIUS 25 mg	R7.70	1 x 1	14	10 Amps	91.00	189703419	AM
132	Promethazine 25mg/ml, injection, 2ml	**1**		319 811		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	PROMETHAZINE HCl FRESENIUS 50 mg	R8.22	1 x 1	14	10 Amps	91.00	189703420	AM
133	Propofol 10mg/ml, injection, 20ml			1 446 630		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	MILSIA 1 % 20 ml	R12.69	5 x 20ml	14	10	96.00	180076590	AM
134	Propofol 10mg/ml, injection, 50ml			195 590		Biotech Laboratories (Pty) Ltd	MAAA0029826	VUV35	MILSIA 1 % 50 ml	R37.54	1 x 50 ml	14	10	96.00	189763039	VI
136	Quinine 300mg, injection, 1ml	**1**		46 610		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	QUININE DIHYDROCHLORIDE FRESENIUS 300 mg/1 ml	R25.25	1 x 1	14	10 Vials	91.00	189706315	AM
137	Ranitidine 25mg/ml, injection, 2ml			822 410		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	CPL Alliance Ranitidine Inj. 50mg/2ml	R2.95	1 x 10	14	500	96.00	180076594	AM
138	Remifentanil 2mg, injection, 5ml			47 070		Pharmacare Limited	MAAA0008452	V2205	Fortiva 2 Inj 5x5ml	R174.80	5 x 5ml	14	5	95.00	181757213	VI
139	Rocuronium 50mg, injection, 5ml	**1**		777 100		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	ROCURONIUM FRESENIUS 10 mg/ml (50 mg/5 ml)	R33.93	1 x 1	14	10 Vials	91.00	180960252	VI

Item No	Item Specification	*ADD	Estimate	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
141	Sodium bicarbonate 4% m/v, injection, 50ml **Product awarded:** **Sodium bicarbonate 4% m/v, injection, 50ml** **1 pack of 60 bags** **Remaining shelf life: 4 - 10 months** **Price vs Pack size:** **1 x 1 bag = R58.15** **1 x 60 bags = R3489.00**	**1**		109 550		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	SODIUM BICARBONATE FRESENIUS 4 % INJECTION	R57.77	1 x 1	14	60 Bags	91.00	180358064	BG
142	Sodium bicarbonate 8.5% m/v, injection, 50ml **Product awarded:** **Sodium bicarbonate 8.5% m/v, injection, 50ml** **1 pack of 60 bags** **Remaining shelf life: 4 - 10 months** **Price vs Pack size:** **1 x 1 bag = R73.82** **1 x 60 bags = R4429.20**	**1**		578 010		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	SODIUM BICARBONATE FRESENIUS 8.5 % INJECTION	R73.33	1 x 1	14	60 Bags	91.00	180358068	BG
143	Sodium chloride 0.9% m/v, injection, 10ml		12 400 540	11 160 486	90%	B Braun Medical (Pty) Ltd	MAAA0040832	VYL89	0.9% Sodium Chloride Injection B. Braun (10ml) (Product Code: 3659990)	R1.48	1 x 1	14	100	96.00	189700088	AM
				1 240 054	10%	Adcock Ingram Critical Care (Pty) Ltd	MAAA0010153	V4222	SODIUM CHLORIDE 0.9% ADCO	R2.30	1 x 100	14	100	50.14		
144	Somatropin 15iu, powder for injection, cartridge + diluent			23 720		Novo Nordisk (Pty) Ltd	MAAA0013414	V2743	NORDITROPIN NORDILET 5 MG	R536.07	1 x 1	14	1	92.00	181808985	EA
145	Somatropin 30iu, powder for injection, cartridge + diluent			24 895		Sandoz SA (Pty) Ltd	MAAA0011663	VVZ69	Omnitrope 10mg	R1 016.00	1 x 1	14	100	91.00	181799365	EA
147	Streptokinase 1.5MU injection			10 155		Actor Pharma (Pty) Ltd	MAAA0183044	V2G28	Fibreaker	R4 640.80	1 x 1	14	5	90.00	189711674	VI
148	Suxamethonium 50mg/ml, injection, 2ml **Product awarded:** **Suxamethonium 50mg/ml, injection, 2ml** **Remaining shelf life: 4 - 10 months**	**1**		635 010		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	SUXAMETHONIUM CHLORIDE-FRESENIUS 100 mg/2 ml	R12.71	1 x 1	14	10 x Amps	91.00	180076785	AM
152	Tranexamic Acid 100mg/ml, injection, 5ml **<u>Product awarded:</u>** **Tranexamic Acid 100mg/ml, injection, 5ml** **1 pack of 5 injections** **<u>Price vs Pack size:</u>** **1 x 1 injection = R37.60** **1 x 5 injections = R188.00**			1 734 980		Pfizer Laboratories (Pty) Ltd	MAAA0019202	V2189	Cyklokapron IV 500	R37.60	1 x 5	14	5	91.00	180076981	AM
153	Vecuronium 4mg, injection, 2ml			53 840		Ranbaxy Pharmaceuticals (Pty) Ltd	MAAA0000384	V4728	MUSCURON	R45.94	1 x 1	14	5	95.00	222000188	EA
154	Verapamil HCl 2.5mg/ml, injection, 2ml			17 910		Pharma-Q (Pty) Ltd	MAAA0016762	V1NK1	Pharma-Q Verapmil Inj. 5mg/2ml	R7.20	1 x 10	14	100	96.00	180076998	AM
156	Vitamin B1 (Thiamine) 100mg/ml, injection, 10ml			412 200		Litha Pharma (Pty) Ltd (Acino Pharma)	MAAA0009244	VGS73	LITHA THIAMINE INJECTION	R37.56	1 x 10	14	1 x 10	100.00	189700006	VI
157	Vitamin B12 (Cyanocobalamin) 1000mcg, injection, 1ml			487 350		P & G South African Trading (Pty) Ltd	MAAA0913191	VJDY7	Neurobion Ampoules	R48.84	3 x 3ml	14	30	91.00	189715773	AM

Item No	Item Specification	*ADD	Estimate	Quantity Awarded	Split	Supplier Name	Central Supplier Database Number	Supplier Code V-Number	Registered Product Name	Delivered Price	Pack Size Offered: Unit Pack	Lead-Time (≤ 14 calendar days)	MOQ	Total Score	National Stock Number	UOM
158	Vitamin K1 (Phytomenadione) 10mg/1ml, injection			773 990		Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	KONAKION	R22.35	1 x 10	14	10	90.00	180146851	AM
159	Vitamin K1 (Phytomenadione) 2mg/0.2ml, injection			3 500 390		Pharmaco Distribution (Pty) Ltd	MAAA0044115	VBVW1	KONAKION	R13.04	1 x 5	14	5	90.00	180953330	AM
160	Water for injection BP, injection, 10ml			37 241 680		B Braun Medical (Pty) Ltd	MAAA0040832	VYL89	Water for Injections B. Braun 10ml (Product Code: 3659980)	R1.27	1 x 1	14	100	96.00	189710871	AM
161	Water for injection BP, injection, 20ml	1		4 112 500		Fresenius Kabi SA (Pty) Ltd	MAAA0007374	VAJL3	WATER FOR INJECTIONS FRESENIUS "FLEXIVIAL" 20 ml	R2.67	1 x 1	14	20 Flexivials	91.00	189710862	AM
162	Zuclopenthixol acetate 50mg, injection, 1ml			228 680		Lundbeck SA (Pty) Ltd	MAAA0031052	VVS90	Clopixol Acuphase 50 mg/ml	R94.90	1 x 1	14	5	90.00	189753243	AM
163	Zuclopenthixol decanoate 200mg/ml, injection, 1ml			2 142 750		Lundbeck SA (Pty) Ltd	MAAA0031052	VVS90	Clopixol Depot 200mg/ml	R49.82	1 x 1	14	5	90.00	180057631	AM

* **ADDENDUM 1**

LEGEND UNIT OF MEASUE (UOM)	
AM	**Ampoule**
BG	**Bag**
BX	**Box**
CA	**Cartridge**
EA	**Each**
SG	**Syringe**
VI	**Vial**

SPECIAL REQUIREMENTS AND CONDITIONS OF CONTRACT

HP06-2021SVP

SUPPLY AND DELIVERY OF SMALL VOLUME PARENTERALS AND INSULIN DEVICES TO THE DEPARTMENT OF HEALTH FOR THE PERIOD 01 MAY 2021 TO 30 APRIL 2024

BID VALIDITY PERIOD: 120 DAYS

CLOSING DATE AND TIME OF BID:

24 JULY 2020 AT 11H00

PLEASE NOTE: AN ERRATUM WILL BE PUBLISHED TO AMEND THE CLOSING DATE TO 28 SEPTEMBER 2020

NO BRIEFING SESSION WILL BE HELD.

TABLE OF CONTENTS

ABBREVIATIONS

API	: Active Pharmaceutical Ingredient
BAC	: Bid Adjudication Committee
B-BBEE	: Broad-Based Black Economic Empowerment
CPA	: Contract Price Adjustment
CSD	: Central Supplier Database
EAN	: European Article Numbering
EME	: Exempted Micro Enterprise
GMP	: Good Manufacturing Practice
MCC	: Medicines Control Council
MHPL	: Master Health Products List
MPC	: Master Procurement Catalogue
NDoH	: National Department of Health
PPPFA	: Preferential Procurement Policy Framework Act
QSE	: Qualifying Small Enterprise
RoE	: Rate of Exchange
SAHPRA	: South African Health Products Regulatory Authority
SARS	: South African Revenue Service
SBD	: Standard Bidding Document
VAT	: Value- Added Tax

BID DOCUMENT CHECK LIST

All bid documents listed below must be sorted, filed and submitted in the exact compilation sequenceas indicated below and the annexure attached.

Submission of bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column.

All bid documents must be signed.

Bidders not complying to any of the requirements may deemed to be non-responsive and will not be considered for evaluation

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
1	CL	Covering Letter				
2	BSRA	Bid Signature. Resolution/Authority to sign bid				
3	BFI	Bid/File Index				
4	PBD4.1	PBD 4.1: Contact Details of Bidder				
5	SBD5.1	SBD 1: Invitation to bid				
6	TCP	Tax Clearance Pin Issued				
7	CSD	CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted.				
8	SBD4	SBD 4: Declaration of interest				
9	PBD9	PBD9: Directors: Categorisation by race, gender and disability				
10	SBD5	SBD5: The National Industrial Participation Programme				
11	SBD6	SBD 6(1): Preference Points Claimed (B-BBEE)				
12	BBBEE	Valid B-BBEE certificate(certified copy of the original) or Sworn Affidavit to claim preference points				

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
13	SBD8	SBD 8: Declaration of Past SCM Practices				
14	SBD9	SBD 9: Certificate of Independent Bid Determination				
15	PBD1	PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid.				
16	PBD1.1	PBD 1.1: List of products offered sourced from third party				
17	PBD1.2	PBD 1.2: Unconditional written undertaking from the third party.				
18	PBD5	PBD5: Good Manufacturing Practice (GMP). Declaration of compliance.				
19	PBD8	PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance.				
20	CIPC	CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates				
21	NC	Proof of company cedings, mergers and name changes				
22	LICMI	Licence to manufacture or import (in the name of the bidder), including all annexures. Certified copies required.				
23	LICM	Licence to manufacture medicines,including all annexures for local manufacturing sites as listed on the MRC of the bidder (applicant). Certified copies required.				
24	MRC	Medicine Registration Certificates (MRC) with all the associated conditions of registration - Certified copies Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order.				

Compilation Sequence	Admin Code	Document Name	N/A	Yes	No	Remark
25	PI	Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI`s must be marked with the relevant item number and be sorted and filed/submitted in numerical order.				
26	PS	Proof of sample submission				
27	BL	Bidder`s item list (List of products offered)				
28	PRICE	Signed Excel Bid Response Pricing Schedule If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation.				
All bid documents listed above must be sorted, filed and submitted in the exact order as indicated above						
Submission of supporting bid documents is compulsory, unless it's not applicable and indicated as such in the "N/A" column						

The bid document check list is available as Annexure A in an excel spreadsheet format and should be completed by all bidders and be submitted in hard copy and as part of the electronic copies of "Set 3: Electronic version of bid documents"

SECTION A

1. LEGISLATIVE AND REGULATORY FRAMEWORK

This bid and all contracts emanating there from will be subject to the Medicines and Related Substances Act, (Act 101 of 1965), Pharmacy Act, (Act 53 of 1974); Patents Act, 1978 (Act 57 of 1978); Trade Marks Act, 1993 (Act 194 of 1993); General Conditions of Contract issued in accordance with Treasury Regulation 16A published in terms of the Public Finance Management Act, 1999 (Act 1 of 1999). The Special Conditions of Contract (SCC) are supplementary to General Conditions of Contract (GCC). Where, however, the Special Conditions of Contract are in conflict with the General Conditions of Contract, the Special Conditions of Contract prevail.

2. BID INFORMATION SESSION

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, published in the Gazette 18 March 2020 no briefing session or public bid opening will be held.

It is strongly recommended that all prospective bidders submit all enquiries to tenders@health.gov.za on time to allow the response to reach the bidders before the tender closes.

3. EVALUATION CRITERIA

The evaluation process will be conducted in phases as follows:

Phase I	Phase II	Phase III	Phase IV
Mandatory and other bid requirements	Product technical compliance	Price and B-BBEE	Recommendation and Award
Compliance with mandatory and other bid requirements	Compliance with technical specifications Test reports received from sample evaluation	Bids evaluated in terms of the 90/10 preference system	Recommendation and award

3.1 PHASE I: MANDATORY REQUIREMENTS

Bidders must submit all required documents indicated above with the bid documents at the closing date and time of the bid. During this evaluation phase, bidder's responses will be evaluated based on the documents submitted under mandatory requirements. This phase is not scored and bidders who fail to comply with all mandatory requirements will be disqualified.

3.1.1 LEGISLATIVE REQUIREMENTS TO THIS BID

Items offered must be registered in terms of section 15 of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and must comply with the conditions of registration for the duration of the contract.

A certified copy of the original Medicine Registration Certificate, issued in terms of section 15(3) (a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), must be included with the bid for all items offered.

The bidder must be indicated as the applicant on the Medicines Registration Certificate.

The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1) (b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A certified copy of the original licence must be submitted by the bidder offering the product.

The bidder offering a product must submit a certified copy of the original licence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.

Where an item offered is not eligible for registeration in terms of section 15(3) (a) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), a package insert of the item must be supplied.

Bidders must comply with the requirements of the Patents Act, 1978 (Act 57 of 1978) and the Trade Marks Act, 1993 (Act 194 of 1993). Where applicable, an explanation for any non-compliance must be

provided. In the case where a product is manufactured under a voluntary license issued by the patent holder of such a product, a letter authorising the marketing of the product, provided to the bidder by the patent holder must be submitted with the bid.

3.1.2 RESPONSIVE BIDS

Bidders are required to submit responsive bids by completing all the prices in the Excel Bid Response. All prices must be submitted with 2 (two) decimals. Document and response fields in the fillible PDF bid document. In this regard, bidder's attention is drawn to the document "Definition of fields in the Bid Response Document" explaining the different fields in the bid document.

3.1.3 BID DOCUMENTS

Bidders are required to submit responsive bids by completing all the prices, mandatory response fields and item questionnaires.

The excel bid response documents i.e. pricing schedule and Directors: Categorisation of race, gender and disability provided forms an integral part of the bid document and bidders must ensure that it is completed without changing the structure thereof. All pages must be signed.

The prices quoted must be furnished as all inclusive (incl. VAT) on the basis of supply and delivery. All prices must be submitted with two (2) decimals.

The bid price offered for a product is deemed to be for the pack size as advertised in the item specification and the unit specified.

Prices submitted must not exceed the ex-manufacturer component of the Single Exit Price inclusive of VAT.

3.1.4 AUTHORISATION DECLARATION

Only the holder of a Medicines Registration Certificate issued in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), may submit a bid.

In the event that the Manufacturer, Packer or other entity, as listed on the certificate of registration are external third parties, the bidder must ensure that all legal, financial and supply arrangements have been mutually agreed upon between the bidder and these third parties.
Where a third party is involved in any capacity, the bidder must submit a duly completed and signed Authorisation Declaration (PBD1) for each such third party.

The National Department of Health reserves the right to verify any information supplied by the bidder in the Authorisation Declaration and, should the information be found to be false or incorrect, the National Department of Health will exercise any of the remedies available to it in the bid documents.

Failure to submit a duly completed and signed Authorisation Declaration, with the required annexure(s), in accordance with the above provisions, will invalidate the bid for such goods or services offered.

No agreement between the bidder and any third party will be binding on the National Department of Health.

3.1.5 TAX COMPLIANCE STATUS

The Central Supplier Database and the tax compliance status PIN are the approved methods of verifying the tax compliance status of a bidder. The South African Revenue Service does not issue Tax Clearance Certificates anymore but has introduced an online provision via eFiling, for bidders to print their own Tax Clearance Certificates which they can submit with their bids or price quotations.

It is a condition of this bid that the tax matters of the bidder be in order at any point in time, or that satisfactory arrangements have been made with SARS to meet the bidder's tax obligations.
It is a requirement that bidders grant a written confirmation when submitting this bid that SARS may, on an on-going basis during the tenure of the contract, disclose the bidder's tax compliance status and, by submitting this bid, such confirmation is deemed to have been granted.

Bidders are required to be registered on the Government's Central Supplier Database and to include in their bid their Master Registration Number (Supplier Number) in order to enable the institution to verify the supplier's tax status on the Central Supplier Database;.

Foreign suppliers with neither South African tax obligations nor history of doing business in South Africa must complete the questionnaire on the SBD1. Where a recommendation for award of a bid has been made to a foreign bidder, the NDOH will submit the bidder's completed SBD1 to the South African Revenue Service to email address: GovernmentInstitute@sars.gov.za. The South African Revenue Service will issue a confirmation of tax obligations letter to the NDOH, confirming whether or not the foreign entity has tax obligations in South Africa

Should the recommended bidder fail to provide written proof of their tax compliance status, the NDOH wull reject the bid submitted by the bidder.

The National Department of Health shall verify the bidder's tax compliance status through the CSD. Where consortia/joint ventures/sub-contractors are involved, each party must be registered on the Central Supplier Database and their tax compliance status will be verified through the Central Supplier Database. Bidders remain responsible to update their CSD information in line with the bid documents submitted for this bid.

4. PHASE II: PRODUCT TECHNICAL COMPLIANCE

4.1 SAMPLES TO BE SUBMITTED TO HEALTH ESTABLISHMENTS

All bidders are required to submit samples, including bidders who are currently supplying the National Department of Health with products to confirm the following:

- Compliance with specifications as set out in the bid document/item specification.
- Compliance of the product with the requirements of the Medicines and Related Substances Act, 1965 (Act 101 of 1965).

Failure to submit samples at both health establishments listed below will invalidate the bid for such items offered. Samples are required to be submitted to each (both) of the addresses indicated below prior to closing date and time of bid:

Mr Dumisani Malele Depot Manager Tel: 011 628 9131 Gauteng: Medical Supplies Depot Store 3 35 Plunkett Avenue Hurst Hill 2092	Mr Nisaar Mia Pharmaceutical Policy Specialist Tel: 021 483 5800 Western Cape: Department of Health 4th Floor, Cape Medical Depot 16 Chiappini Street Cape Town 8001

- No samples must be sent to the National Department of Health.
- Samples must be marked with the bid number, the item number as well as the bidder's name and address.
- Bidders must submit at least one original pack of each offer for evaluation.
- It is the responsibility of the bidder to ensure that samples have been received at the addresses provided above.
- All samples for awarded items will be retained for the period of the contract.
- All samples must be a true representation of the product which will be supplied.
- All samples submitted must include the package insert or document detailing professional information approved by the MCC or SAHPRA.
- Proof of sample submission, including a signed copy of the item list as received by the sample evaluation site, must be submitted with the bid documents at the closing date and time of the bid.

4.2 COMPLIANCE WITH SPECIFICATIONS

Items must comply with the specification as detailed in the bid document.

5. PHASE IV: PREFERENCE POINT SYSTEM

5.1 A MAXIMUM OF 80 OR 90 POINTS IS ALLOCATED FOR PRICE ON THE FOLLOWING BASIS:

80/20 or 90/10

$$Ps = 80\left(1 - \frac{Pt - P\min}{P\min}\right) \quad \text{or} \quad Ps = 90\left(1 - \frac{Pt - P\min}{P\min}\right)$$

Where

Ps	=	Points scored for price of bid under consideration
Pt	=	Price of bid under consideration
Pmin	=	Price of lowest acceptable bid

5.2 POINTS AWARDED FOR B-BBEE STATUS LEVEL OF CONTRIBUTOR

In terms of Regulation 6(2) and 7(2) of the Preferential Procurement Regulations, preference points must be awarded to a bidder for attaining the B-BBEE status level of contribution in accordance with the table below:

B-BBEE Status Level of Contributor	Number of points (90/10 system)	Number of points (80/20 system)
1	10	20
2	9	18
3	6	14
4	5	12
5	4	8
6	3	6
7	2	4
8	1	2
Non-compliant contributor	0	0

For this tender, the 90/10 preference point system will be applied.

- Bidders are required to complete the preference claim form (SBD 6.1), and submit a valid certified copy of the original B-BBEE status level verification certificate, at the closing date and time of the bid in order to claim the B-BBEE status level point.
- The points scored by a bidder in respect of the level of B-BBEE contribution will be added to the points scored for price.
- Only bidders who have completed and signed the declaration part of the preference claim form and who have submitted a certified copy of an original B-BBEE status level certificate issued by a registered auditor, accounting officer (as contemplated in section 60(4) of the Close Corporation Act, 1984 (Act No. 69 of 1984)) or an accredited verification agency will be considered for preference points.
- Exempted Micro Enterprises (EME's) and Qualifying Small Enterprices (QSE's) must submit a Sworn Affidavit as prescribed by the B-BBEE Commssion, Practice Guide 01 of 2019.
- Sworn Affidavits submitted by EME's and QSE will strictly be evaluated according the the guidelines as prescribed by the B-BBEE Commission.
- If the bidder fails to comply with the paragraphs above, the bidder will be deemed not to have claimed preference points for B-BBEE status level of contribution and will therefore be allocated a zero (0). The National Department of Health may, before a bid is adjudicated or at any time, require a bidder to substantiate claims it has made with regard to preference claimed. The points scored will be rounded off to the nearest two (2) decimals. In the event that two (2) or more bids have scored equal total points, the contract will be awarded to the bidder scoring the highest number of preference points for B-BBEE.
- A contract may, on reasonable and justifiable grounds, be awarded to a bid that did not score the highest number of points.

6. PREFERENCE FOR LOCALLY PRODUCED PRODUCTS

The National Department of Health reserves the right to consider locally produced products offered. Bidders are required to indicate on the Excel Bid Response Document where the products are manufactured.

In order to provide preference to locally produced products, the definition of a locally produced product will be limited to product formulation and conversion processes that use materials and components to manufacture medicines (including importation of raw material of active pharmaceutical ingredients (API) and of excipients for production of finished products) in the Republic of South Africa.

Where the National Department of Health gives preference to locally produced products, the quantities for these items will be allocated and awarded proportionately to locally produced products, provided this does not negatively impact upon security of supply and affordability.

Bids for products that qualify for this preference must comply with all of the following criteria:

- The South African Health Product Authority (SAHPRA) certificate of registration for a product lists the primary site of production as one that is located in the Republic of South Africa;
- The bidder offering a product must be the holder of a licence to manufacture or import medicines issued in terms of section 22C (1) (b) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) including all annexures. A certified copy of the original licence must be submitted by the bidder offering the product.
- The bidder offering a product must submit a certified copy of the original licence to manufacture medicines, including all annexures for local manufacturing sites listed on the MRC of the bidder who must also be the applicant.
- The reference price as published by National Department of Health has not been exceeded (if applicable);
- The site/s of manufacture and/or packaging for the product offered is located in South Africa;
- Demonstrated capacity to service the required volumes as evaluated in terms of the data provided in the Excel Bid Response Document;
- Previous supplier performance;
- Compliance to all other aspects contained in these Special Conditions of Contract

7. VALUE ADDED TAX

All bid prices must be inclusive of 15% Value-Added Tax. Failure to comply with this condition will invalidate the bid.

8. SUBMISSION OF BIDS

All bid documents listed below must be sorted, filed and submitted in the exact compilation sequence as indicated below and the annexure attached.

Submission of bid documents is mandatory, unless it's not applicable and indicated as such in the "N/A" column in the Bid Document Check List.

All bid documents must be signed.

Bidders not complying to any of the requirements may be deemed to be non-responsive and will not be considered for evaluation.

- Covering Letter i.e. limited stock availability of any item offered, non-compliance;
- Status relating to TAX, B-BBEE, License to Manufacture, Certificates etc. Bid Signature;
- Resolution/Authority to sign bid;
- Bid/File Index;
- PBD 4.1: Contact Details of Bidder;
- SBD 1: Invitation to bid;
- Tax Clearance Pin Issued;
- CSD Registration report - A certified copy of latest and complete report. Note: CSD summary report will not be accepted;
- SBD 4: Declaration of interest;
- PBD9: Directors: Categorisation by race, gender and disability;
- SBD5: The National Industrial Participation Programme;
- SBD 6(1): Preference Points Claimed (B-BBEE);
- Valid B-BBEE certificate (certified copy) or Sworn Affidavit to claim preference points;
- SBD 8: Declaration of Past SCM Practices;
- SBD 9: Certificate of Independent Bid Determination;
- PBD1: Authorisation Declaration Note: Non-compliance to submission of a valid authorisation declaration, where applicable, may invalidate the bid;
- PBD 1.1: List of products offered sourced from third party;
- PBD 1.2: Unconditional written undertaking from the third party;
- PBD5: Good Manufacturing Practice (GMP). Declaration of compliance;
- PBD 8: Special Requirements and Conditions of Contact. Declaration of compliance;
- CIPC/CIPRO or proof of ownership/shareholding. Certified copies of registration certificates;
- Proof of company cedings, mergers and name changes;
- Certified copy of Licence to manufacture or import (in the name of the bidder), including all annexures;
- Certified copy of Licence to manufacture medicines, including all annexures for local manufacturing sites as listed on the MRC of the bidder (applicant);

- Certified copies of Medicine Registration Certificates (MRC) with all the associated conditions of registration (Annexure). Note: All MRC's must be marked by the bidder with the relevant item number and be sorted and filed in numerical order;
- Original Package Insert (PI) or document detailing professional information approved by the Medicines Control Council (MCC) or the South African Health Products Regulatory Authority (SAHPRA) for each product offered. Note: All PI`s must be marked with the relevant item number and be sorted and filed/submitted in numerical
- order;
- Proof of sample submission;
- Bidder`s item list (List of products offered); and
- Signed Excel Bid Response Pricing Schedule (All prices must be submitted in 2 (two) decimals). If the Excel Bid response Pricing Schedule is not signed in the space provided, the bid will not be considered for evaluation

9. COMPLETION OF DOCUMENTS AND BID SUBMISSION

Bidders are required to submit three sets of bid documents according to the instructions below. All three sets must be submitted not later than the closing date and time. Set 2 and Set 3 must be included on a CD with Set 1 and submitted in a sealed package. The full name and address of the bidder, including the return address, the bid number and the closing date must be clearly indicated on the package. All fields must be completed. Where information requested is not relevant this should be indicated with N/A.

Set 1: Hard copy legally binding bid documents

Bidders must complete all SBD, PBD and Bid Response forms in black ink, typed. Where no electronic entry field is provided bidders must complete the forms in black ink, handwritten in capital letters. The signed hard copy of the bid document will serve as the legal bid document.

Bidders must submit their complete bid in hard copy format (paper document). The Chief Executive Officer, Chief Financial Officer, or authorised designee of the entity submitting the bid must sign the official signature pages.

All pages in the complete bid document must be initialed by same with black ink. The use of correction fluid is not acceptable. Any change/s must be clearly indicated and initialed.

As the National Department of Health complies with the regulations made under the Disaster Management Act, 2002, published in the Gazette 18 March 2020 no briefing session or public bid opening will be held. However, Bidders must still ensure that bids are delivered on time to the correct address and deposited in the Tender Box. Late bids will not be accepted for consideration

Bidders must refrain from using binding methods like coil, comb, wire velobind, screw binding etc. It is requested that bidders pre-punch two holes on the left hand side of bid documents suitable for filing in a two hole lever arch file. Bid documents should be tied in parcels using string or rope that can be easily untied for filing purposes.

Set 2: PDF of Hard Copy, signed legal documents. (i.e. pdf of Set 1)

Bidders must submit a PDF version of the entire signed hardcopy bid, including all certificates and documents requested.

Set 3: Electronic version of bid documents

Bidders must submit the electronic versions (editable pdf) of all SBD and PBD documents, Bid Response Document and other relevant spreadsheets in Excel (not pdf).

All three sets of information must be submitted in order for the bid to be evaluated.

Bidders must ensure that the price quoted for a product (line item) on the Bid Response Document is for the unit pack as specified. No conversion factors will be applied.

.

10. LATE BIDS

Bids received after the closing date and time, at the address indicated in the bid documents, will not be accepted for consideration and, where practical, be returned unopened to the bidder.

11. COUNTER CONDITIONS

Bidders' attention is drawn to the fact that amendments to any of the bid conditions or setting of counter conditions by bidders may result in the invalidation of such bids.

12. FRONTING

The National Department of Health supports the spirit of broad based black economic empowerment and recognises that real empowerment can only be achieved through individuals and businesses conducting themselves in accordance with the Constitution and in an honest, fair, equitable, transparent and legally compliant manner. Against this background, the National Department of Health condemns any form of fronting.

The National Department of Health, in ensuring that bidders conduct themselves in an honest manner will, as part of the bid evaluation processes, conduct or initiate the necessary enquiries/investigations to determine the accuracy of the representation made in bid documents. Should any of the fronting indicators as contained in the Guidelines on Complex Structures and Transactions and Fronting, issued by the Department of Trade and Industry, be established during such enquiry/investigation, the onus will be on the bidder/contractor to prove that fronting does not exist. Failure to do so within a period of 14 days from date of notification, may invalidate the bid/ contract and may also result in the restriction of the bidder/contractor to conduct business with the public sector for a period not exceeding 10 years, in addition to any other remedies the National Treasury may have against the bidder/contractor concerned.

13. SUPPLIER DUE DILIGENCE

The National Department of Health reserves the right to conduct supplier due diligence prior to final award or at any time during the contract period. This may include site visits to assess whether an item is manufactured at the site specified in the bid and the site complies with quality criteria.

14. COMMUNICATION

The National Department of Health, may communicate with bidders where clarity is sought after the closing date and time of the bid and prior to the award of the contract, or to extend the validity period of the bid, if necessary.

Any communication to any government official or a person acting in an advisory capacity for the National Department of Health in respect of this bid between the closing date and the award of the bid by the bidder is discouraged.

All communication between the bidder and the National Department of Health, must be done in writing.

15. CONTACT DETAILS

Postal address

Directorate: Affordable Medicines

Private Bag X828

PRETORIA

0001

Physical address

Directorate: Affordable Medicines

Civitas Building

242 Struben Street

Cnr Thabo Sehume Street

Pretoria

0002

Please use the following e-mail address for any queries relating to bidding process:

- tenders@health.gov.za

SECTION B

16. CONTRACT PERIOD

The contract shall be for the period from 01 May 2021 to 30 April 2024.

17. PARTICIPATING AUTHORITES AND OTHER HEALTH ESTABLISHMENTS

Participating Authorities and Health Establishments which will be participating authorities in this contract are National Departments, Provincial Departments and orther institutions as approved by the accounting officer.

Provincial Departments:

- Eastern Cape;
- Free State;
- Gauteng;
- KwaZulu-Natal;
- Limpopo.
- Mpumalanga;
- Northern Cape;
- North West;
- Western Cape; and

Other Institutions:

- Nelson Mandela Childrens' Hospital

18. REGISTRATION ON DATABASES OF PARTICIPATING AUTHORITIES

All contracted suppliers must register on the supplier databases of Participating Authorities within 30 days after award of contract.

Failure to meet this requirement will result in the inability to process payment for goods.

19. POST AWARD PARTICIPATION

Regulation 16A6.6 of the Treasury Regulations for Departments, Trading Entities, Constitutional Entities and Public Entities, issued in terms of the Public Finance Management Act, 1999, (Act 1 of 1999), states that the Accounting Officer/Accounting Authority may, on behalf of a department, constitutional institution or public entity, request to participate in any contract arranged by means of a competitive bidding process by any organ of state, subject to the written approval of such organ of state and the relevant contractors.

20. AWARD CONDITIONS

The National Department of Health reserves the right to award contracts to more than one contractor for the same item.
The National Department of Health reserves the right to negotiate prices.
The National Department of Health reserves the right to award the same item as a multiple award to various contractors (two or more) to address high volume requirements, security of supply and product availability.

The following are examples of considerations which may be taken into account when contemplating a multiple award:

- Source of Active Pharmaceutical Ingredient (API) and actual manufacturing site;
- Capacity to meet expected demand as per published estimates in the Excel Bid Response Document;
- Estimated volume to be supplied;
- Risk to public health if the item is not available;
- Past compliance of the bidder with contractual obligations.

In cases where the tender does not achieve the most economically advantageous price, the National Department of Health reserves the right not to award that item. In the case of medicines for chronic conditions, pack sizes suitable for a 28-day treatment cycle are required. Should a 30-day or other pack size be offered, no conversion factor will be applied. Direct comparisons will be made between the 28-day and other pack sizes during evaluation. Similarly, no conversion factors will be applied in cases where a pack size other than that specified is offered.

The National Department of Health may change treatment protocols and/or product formulations where required, due to emerging clinical evidence, disease profiles, safety or resistance patterns and availability of items registered in terms of the Medicines and Related Substances Act, 1965, (Act 101 of 1965) at the date and time of bid closure. In these circumstances, the National Department of Health reserves the right to cancel the contract for an item, or adjust the quantity awarded based on expected changes in projected demand. The Department of Health will notify the contracted supplier within a reasonable time of the expected change. However, in cases where patient safety is a concern, these changes may be implemented with immediate effect.

20.1 SPLIT AND MULTIPLE AWARDS

The National Department of Health reserves the right to issue split or multiple awards, where necessary, to ensure security of supply.

The following will be taken into consideration when contemplating a split award:

- Source of API and manufacturing site.
- Capacity to meet expected demand as per published estimates in the Bid Response Document.
- Estimated volume to be supplied.
- Risk to public health if the item is not available.
- Past compliance of the bidder with contractual obligations.

Two-way split awards will be made in accordance with the following schedule based on the points scored:

Category	Difference between points scored	Recommended percentage split
A	Equal points	50/50
B	< 5 points	60/40
C	>5-10 points	70/30
D	>10-20 points	80/20
E	>20 points	90/10

Where a split for more than 2 suppliers is contemplated, the following formula may be used to allocate volumes for award:

- For a three way split: Supplier share = 33.3% + (supplier score - mean score) x 2.3%
- For a four way split: Supplier share = 25% + (supplier score - mean score) x 2%

20.2 THERAPEUTIC CLASS AWARDS

The Policy for Classifying Medicines into Therapetic Classes for Purposes of Therapeutic Interchange defines a therapeutic class as a group of medicines which have active ingredients with comparable therapeutic effects. Medicines in a therapeutic class may or may not belong to the same pharmacological class, may differ in chemistry or pharmacokinetic properties, and may possess different mechanisms of action, result in different adverse reactions, have different toxicity and drug interaction profiles. In most cases, these medicines have close similarity in efficacy and safety profiles, when administered in equipotent doses for a specific indication.

The ministerially appointed National Essential Medicines List Committee (NEMLC) formulates and revises the Standard Treatment Guidelines (STGs) and Essential Medicines List (EML). Therapeutic classes are mentioned in the “Medicine treatment” section of the national STGs which provides a class of medicines followed by an example such as, HMGCoA reductase ihibitors (Statins) e.g. simavastatin. These therapeutic classes have been designated where none of the members of the class offer any significant benefit over member of the class for a specific indication. The NEMLC will designate therapeutic classes for a condition, where appropriate.

Such therapeutic classes may be used during the contracting process to achieve the most economically advantageous contract, offer the market the largest volume and increase the number of competitors, thereby offering the opportunity for cost efficiencies by stimulating robust competition.

A single member of the class may be awarded.

Therapeutic Class and Series Number	Therapeutic class description	Members of the therapeutic class
Class 1	Surfactant - group 1	Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial Vs Natural Phospholipids (Poractant alpha), intra-tracheal solution, 120mg in 1.5ml, 1.5ml
Class 2	Surfactant - group 2	Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial Vs Natural Phospholipids (Poractant alpha), intra-tracheal solution, 240mg in 3ml, 3ml

21 NEGOTIATIONS

The National Department of Health reserves the right to negotiate with the bidders prior to award and with the successful bidder(s) post award.

22. NON-COMMITMENT

The National Department of Health reserves the right not to award, to award in part, or in full.
The right is also reserved to withdraw or amend any of the bid conditions, by notice, in writing to all bidders prior to closing of the bid and post award
In the event that an incorrect award has been made, the National Department of Health reserves the right to remedy the matter in any manner it may deem fit.

23. PRICE REVIEW

The National Department of Health envisages three types of price review processes for the duration of this contract:

- A routine adjustment to mitigate foreign exchange fluctuations;
- An exceptional adjustment to mitigate significant short-term foreign exchange fluctuations; and

- A systematic review of prices for comparable products available in the international market place.

23.1 ELIGIBILITY RELATING TO RATE OF EXCHANGE ADJUSTMENTS

Eligibility for price adjustments relating to foreign exchange risk depends on:
The submission of a complete price breakdown per instructions below for all relevant products; and

Assessment of the rationality of this price breakdown by the National Department of Health.

23.1.1 INSTRUCTIONS FOR PRICE BREAKDOWN

- The price breakdown must be completed on the signed bid response document as well as the electronic version. The delivered price must be divided across five components
  - Active Pharmaceutical Ingredients (API);
  - Formulation;
  - Packaging;
  - Logistics (this includes transportation, warehousing and distribution);
  - Gross margin (remaining portion).
- The sum of these categories must be equal to 100% of the delivered price for the line item.
- The local + imported portions of the first three components must add up to 100% within each component (e.g. Portion of API attributable to local + Portion of API attributable to import = 100% of specific API component).
- VAT must be apportioned equally across all components and not regarded as a separate component.
- Labour must be apportioned appropriately across the relevant components.
- Breakdown must be in percentage format to the closest whole percentage (e.g. 20%).
- The National Department of Health reserves the right to engage with bidders to verify any of the components of the bid price, which may include audit of invoices and related documentation.

23.2 PRICE ADJUSTMENTS RELATING TO FOREIGN EXCHANGE RISK

Only the portion of the bid price facing foreign exchange risk will be adjusted. This portion is determined by the price breakdown on the signed bid submission.
Adjustments are always calculated using the original awarded contracted price as the base.

Price adjustments relating to foreign exchange will be based on the percentage change between the relevant base average rate of exchange (RoE) and an adjustment average RoE.
Rates are sourced from the Reserve Bank (www.resbank.co.za).

Eligibility for favourable Contractual Price Adjustments may be withdrawn in light of evidence of poor compliance with contractual obligations.

Base average RoE for this tender will be as follows, per currency:

Currency	Base Average Rates of Exchange Average for the period 1 January 2020 to 30 June 2020
Rand per US Dollar	16.61
Rand per Br Pound	20.90
Rand per Euro	18.30
Rand per Yuan Renminbi	2.34
Rand per Indian Rupee	0.22
Rand per Danish Krone	2.43

Should the bidder make use of any currency not mentioned above, the bidder must stipulate this clearly and submit the calculated average RoE for the period 1 January 2020 to 30 June 2020 using the South African Reserve Bank published rates for the specific currency.

23.3 APPLICATION FOR CONTRACTUAL PRICE ADJUSTMENTS

Scanned copies of signed applications for price adjustments must be received by the National Department of Health prior to the submission dates detailed in the tables below.
Where no application for an adjustment relating to foreign exchange has been received and such an adjustment would be favourable to the Department, this will be implemented automatically.
Foreign exchange adjustments may never result in a price exceeding the current Single Exit Price, ex Logistics.

23.4 ROUTINE PRICE ADJUSTMENTS

Schedules for routine price reviews, and periods for calculating adjustment average RoE are detailed in the table below:

Review	Period for calculating adjustment average RoE	Submission of request for proce review to reach the office by	Date from which adjusted prices will become effective
1	01 May 2021 - 31 October 2021	03 November 2021	01 December 2021
2	01 November 2021 - 30 April 2022	03 May 2022	01 June 2022
3	01 May 2022 - 31 October 2022	03 November 2022	01 December 2022
4	01 November 2022 - 30 April 2023	03 May 2023	01 June 2023
5	01 May 2023 - 31 October 2023	03 November 2023	01 December 2023

23.5 EXCEPTIONAL PRICE ADJUSTMENTS

Suppliers may request exceptional price adjustments according to the schedule in the table below. These will be activated if the absolute change between the base RoE and the three month retrospective average RoE indicated in the table below fluctuates by more than 10%.

Review	Period for calculating adjustment average RoE	Submission of request for proce review to reach the office by	Date from which adjusted prices will become effective
0.1	01 May 2021 - 31 July 2021	03 August 2021	01 September 2021
1.1	01 November 2021 - 31 January 2022	03 February 2022	01 March 2022
2.1	01 May 2022 - 31 July 2022	03 August 2022	01 September 2022
3.1	01 November 2022 - 31 January 2023	03 February 2023	01 March 2023
4.1	01 May 2023 - 31 July 2023	03 August 2023	01 September 2023
5.1	01 November 2023 - 31 January 2024	03 February 2024	01 March 2024

Suppliers who received exceptional adjustments will receive routine adjustments based on the preceding three months, rather than the usual six month historical average exchange rate. The periods for calculating adjustment average RoE in these instances are detailed in the table below:

Review	Period for calculating adjustment average RoE	Submission of request for proce review to reach the office by	Date from which adjusted prices will become effective
1	01 August 2021 - 31 October 2021	03 November 2021	01 December 2021
2	01 February 2022 - 30 April 2022	03 May 2022	01 June 2022
3	01 August 2022 - 31 October 2022	03 November 2022	01 December 2022
4	01 February 2023 - 30 April 2023	03 May 2023	01 June 2023
5	01 August 2023 - 31 October 2023	03 November 2023	01 December 2023

23.6 PRICE ADJUSTMENTS BASED ON A SYSTEMATIC REVIEW

The National Department of Health reserves the right to review international prices to identify lowest comparable global prices.

Where this review identifies any prices that are lower than contract prices the National Department of Health will enter into price negotiations with the contracted supplier.

Where the outcome of this negotiation is deemed unfavourable, the National Department of Health reserves the right to terminate the award for the item in question.

24. QUALITY

Products must conform to the conditions of registration of the product in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965) for the full duration of this contract.

25. DELIVERY AND QUANTITIES

25.1 DELIVERY BASIS

Firm lead times for delivery must be quoted for the duration of the contract period.

Transit and storage conditions applicable to the relevant products must be adhered to.

The initial lead time as proposed in the bid response document will be calculated from date of award of the contract and NOT the date of placement of the first order. This period may not exceed 75 calendar days from the date of award.

Lead time within the contract period is defined as the time from submission of order to supplier to time of receipt by the Department, as confirmed by the Proof of Delivery document. This lead time may not exceed 14 calendar days.

Failure to comply with the contractual lead time will result in penalties being enforced as per paragraph 21 and 22 of the General Conditions of Contract.

25.2 QUANTITIES

The quantities reflected in the bid are estimated quantities and no guarantee is given or implied as to the actual quantity which will be procured during the contract period. Fluctuations in monthly demand may occur.

Proposed minimum order quantities (MOQs) should facilitate delivery directly to health establishments. The National Department of Health reserves the right to negotiate MOQs where necessary. Where consensus regarding MOQs cannot be reached, the bid may not be awarded.

Suppliers are required to maintain sufficient buffer stock to meet at least two-months demand for all items, aligned with the needs of Participating Authorities.

SECTION C

26. SUPPLIER PERFORMANCE MANAGEMENT

26.1 Supplier performance management will be the responsibility of Participating Authorities with oversight from the National Department of Health and, where supplier performance disputes cannot be resolved between the contractor and the Participating Authority, National Treasury: Transversal Contracting Chief Directorate and National Department of Health must be informed for corrective action.

The National Department of Health, in collaboration with the Participating Authorities, will monitor the performance of contracted suppliers in terms of this contract, including but not limited to the following:

- Compliance with reporting requirements according to reporting schedule and reporting mechanism.
- As a minimum, suppliers will be required to submit the following information in a specified format and via a mechanism defined by the National Department of Health:
  - All transactional data relating to orders;
  - A monthly age analysis;
  - Production pipeline data and forecast including:
  - Number of units of the item available (stock on hand);
  - Number of units of the item in Quality Assurance, awaiting release;
  - Number of units of the item in the current month's production plan.
  - Status of outstanding orders.
- Attendance of compulsory quarterly meetings
  - The National Department of Health will hold quarterly meetings with suppliers which will include, but not be limited to, a review of supplier performance and forecasted demand for the next quarter. Suppliers may be required to present continuous improvement initiatives aimed at improving efficiencies in the supply chain to benefit both suppliers and the Department of Health.

- The Participating Authorities shall impose penalties, where deemed necessary, as per Paragraph 21 and 22 of the General Conditions of Contract.
- Non-compliance of contracted suppliers to the terms and conditions of this contract may influence participation in future contracts.

- Contractors should note that each individual purchasing institution is responsible for generating the order(s) as well as for the payment(s) thereof.
- Contractors should note that the order(s) will be placed as and when required during the contract period and delivery points will be specified by the relevant purchasing institution(s).
- The instructions appearing on the official order form regarding the supply, dispatch and submission of invoices must be strictly adhered to and under no circumstances should the contractor deviate from the orders issued by the purchasing institutions.
- The Department of Health is under no obligation to accept any quantity which is in excess of the ordered quantity.
- In order to facilitate efficient implementation of the direct delivery strategy, contracted suppliers must pack orders for the health establishment as per the purchase order.
- Only orders made using an official, authorised purchase order format are valid.
- Suppliers are required to acknowledge receipt of all purchase orders received from Participating Authorities, in a manner stipulated by the relevant Participating Authority.
- Changes to any quantities ordered may only be made upon receipt of an amended purchase order.
- The Participating Authorities reserve the right to cancel orders where the lead time exceeds the delivery lead time specified in the contract and may, at their discretion, purchase supplies of a similar quality and up to the same quantity in substitution of the goods not supplied in conformity with the contract (as per paragraph 21.6 of the General Conditions of Contract).
- In cases where an order is received which appears to be irrational or misaligned with estimates, the contracted supplier must liaise with the relevant Participating Authority prior to processing the order.

26.2 DELIVERY ADHERENCE

- Products and related documentation must be delivered in accordance with the terms, conditions and delivery instructions stipulated on the purchase order.
- The information on invoices and documents relating to delivery must comply with the minimum data requirements as defined by the National Department of Health.
- Invoices must reflect both the "proprietary name "(brand name"/"trade name") which is unique to a particular medicine, and which is the name approved in terms of section 15(4) of the Medicines and Related Substances Act, 1965 (Act 101 of 1965), and the item description as it appears in the contract

circular and Master Procurement Catalogue (MPC), or Master Health Product List (MHPL), which will replace the MPC.

- Original invoices and proof of delivery must be authorised by a delegated official at the designated delivery point. These documents must be delivered to the authority responsible for payment. This may or may not be the same as the delivery address stipulated on the purchase order. Suppliers are required to know where documents must be delivered.
- The supplier must ensure that products are delivered in accordance with the appropriate conditions of storage, as per product's conditions of registration. Delivery is deemed to terminate upon signature of receipt by the delegated official.
- Discrepancies between invoice and physical stock, or damaged stock, will be reported to the contracted supplier within a reasonable time or as arranged with the supplier. This time period must make provision for the quantities received to be checked upon receipt of delivery.
- Contracted suppliers will be responsible for collection of goods delivered erroneously, or in the incorrect condition as formally arranged in consultation with the purchasing authority. The Participating Authorities may recoup any expenses associated with failure to collect such goods in accordance with the agreement

26.3 CONTINUITY OF SUPPLY

- Contracted suppliers must have at least two months' supply of the estimate at the start of the contract.
- Contractors must maintain sufficient buffer stock throughout the duration of the contract.
- Contractors must inform National Department of Health at first knowledge of any circumstances that may result in interrupted supply, including but not limited to:
  - regulatory action which may impact on their GMP status or that of entities on which they are reliant;
  - any anticipated problems associated with the availability of active pharmaceutical ingredient (API);
  - industrial action
  - challenges with manufacturing pipeline;
  - any other supply challenges.
- Contractors must direct official communication relating to continuity of supply to stockalert@health.gov.za, as well as Participating Authorities.
- Contractors must direct official communication relating to payment challenges to medacc@health.gov.za, as well as Participating Authorities.

- All official communication must include detail of corrective actions taken by the contracted supplier to ensure continuity of supply.
- It is the responsibility of the contracted supplier to ensure continuous availability and supply of contracted items. In the event that the contracted supplier is unable to supply, the contracted supplier id required to source alternative product of acceptable quality and up to the same quantity as required for a period of not more than three months. In the case of a multiple award, the alternative product should not be sourced from another contracted supplier for the same product.
- In the event that a contracted supplier is unable to supply in the short term, the National Department of Health reserves the right to proportionally reallocate volumes to an alternative contracted supplier for the duration of the contracted supplier's inability to supply.
- Prior to the supply of an alternative product can be undertaken, the contracted supplier is required to submit the samples of the product to be supplied to the two health establishments as listed in section 4.The contracted supplier is also required to furnish the Department of Health with the following information:
- Name of the product to be supplied;
- The quantities to be supplied;and
- The period for which the product will be supplied.
- The alternative product must be supplied at the current price of the contracted item.
- This provision is only applicable for emergency supply and cannot be used for routine and continuous supply of the product.
- Suppliers may be required to pay penalties for supply exceeding the contractual lead time as stipulated in the General Conditions of Contract Paragraph 22.
- In terms of the General Conditions of Contract and Special Requirements and Conditions of Contract, the Participating Authorities may purchase outside the contract in order to meet its requirements if the item is urgently required and is not immediately available.

26.4 REPORTING

National Department of Health will provide the requirements for reporting and successful bidders will be assisted with complying with these requirements.

The National Department of Health may, from time to time and within reason, add to the reporting requirements. Any changes to reporting requirements or the reporting mechanism will be communicated in writing by the Directorate: Affordable Medicines.

27. PACKAGING, LABELLING AND BARCODES

27.1 PACKAGING

- Suppliers must ensure that products delivered are received in good order at the point of delivery. Packaging must be suitable for further dispatch, storage and stacking according to Good Wholesaling Practice and Good Distribution Practice.
- Packaging must be suitable for transportation and should prevent exposure to conditions that could adversely affect the stability and integrity of the product.
- The packaging must be uniform for the duration of the contract period. All products must be packaged in acceptable containers, specifically developed for the product.
- The number of units per shipper pack or original carton must be completed in the Bid Response Document.
- Where a particular stacking and storage configuration is recommended by the supplier, this should be clearly illustrated on the outer packaging.
- Where the contents of the shipper pack represent a standard supply quantity of an item, the following must be adhered to:
  - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
  - The contents must be packed in neat, uniform rows and columns that will facilitate easy counting when opened.
  - Where the contents of a shipper pack represent a non-standard supply quantity, the following must be adhered to:
  - Outer packaging flanges must be sealed with suitable tape that will clearly display evidence of tampering;.
  - The shipper pack must contain only one product, mixing of multiple products in a single shipper is not allowed;.
  - The outer packaging must be clearly marked as a "Part Box".

27.2 LABELLING

- All containers, packaging and cartons must be clearly labelled. Bulk packs must be labelled in letters not less than font size 48.
- The following information must be clearly and indelibly printed on all shipper packs, including any part boxes:
  - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL), which will replace the MPC.
  - Registered product name (if applicable);
  - Number of units in pack
  - Batch number;
  - Expiry date;
  - Storage conditions;
  - Barcode.
- Where the contents of the shipper pack require special attention in terms of storage and/or handling, e.g. thermolabile, high-scheduled or cytotoxic products, such instructions must be clearly and visibly indicated on the outer packaging on a brightly coloured background.
- Unit packs must be labelled in accordance with Regulation 10 of the General Regulations published in terms of the Medicines and Related Substances Act, 1965 (Act 101 of 1965). The label must include a barcode suitable for the identification and tracking of medication.

27.3 BARCODES

- All unit and shipper packs must be marked with the appropriate barcode number and symbology.
- The European Article Numbering Code 13 (EAN 13) has been accepted as standard.
- Suppliers are encouraged to include a 2D barcode or similar on their packaging that will include the following information:
  - Item name as contained in the contract circular and the Master Procurement Catalogue (MPC), or Master Health Products List (MHPL) which will replace the MPC.
  - The "proprietary name (brand name"/"trade name") unique to a particular medicine, as approved by MCC or SAHPRA;
    - Dosage form and strength;
    - Pack size;

- Batch number;
- Expiry date.

28 SHELF LIFE

- Unless MCC or SAHPRA, has approved a shorter shelf life, products must have a shelf-life of at least 12 months upon delivery.
- Contracted suppliers may apply in writing to Participating Authorities to supply a product with a shorter shelf life provided that:
  - Applications are accompanied by an undertaking that such short-dated products will be unconditionally replaced or credited before or after expiry; and
  - Applications are approved by the Participating Authorities before execution of orders; and
  - Upon notification of remaining expired stock such products will be collected by the supplier at their own cost; and
  - Failure to collect the products within 30 days after written notification to the supplier will result in the disposal of the product by the Participating Authority for the account of the supplier.
- If short-dated products are delivered without the aforementioned undertaking the following discount formula will be applied for invoicing of short-dated products:
  - A = (12 – months to date of expiry) x 2% x consignment value short dated product. Therefore, amount to be invoiced is: Consignment value minus A, where A is the value of the outcome of the discount formula.
- Unless otherwise agreed to, any Participating Authority may, without prejudice, decline to accept product with a shelf-life of less than 12 months.

29. CEDING, MERGERS, TAKE OVERS AND CHANGES IN SUPPLIER DETAILS

Where a contracted supplier plans to merge with, or is going to be acquired by, another entity or plans to cede a contract the contracted supplier must inform the National Department of Health in writing at first knowledge of such an event.

Where a contracted supplier plans to cede a contrated item to another supplier, the contracted supplier must submit an official request in writing to the NDOH, three months prior to the proposed effective date.

The NDOH reserves the right to accept or decline the request to cede the contractual obligations to the new supplier under the prevailing conditions of contract or to cancel the contract.

The contracted supplier is obliged to supply the contracted item under the prevailaing conditions of contract, until such time that the NDOH has approved the request to cede the item to another supplier.

The contracted supplier must inform the National Department of Health at first knowledge of any changes to address, name, or contact details and effect these changes on the Central Supplier Database.

30. CANCELLATION OF THE CONTRACT

Cancellation of a contract will only be considered after compelling evidence to support the request has been submitted to the satisfaction of the Department of Health.

The contracted supplier is obliged to supply the contracted item under the prevailaing conditions of contract, until such time that the NDOH has approved the request to cancel the item.

31. THIRD PARTIES

Participating Authorities will not make a payment to or consult with a third party.
No third party is entitled to put an account of a Participating Authority on hold.

END

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
1	Acetylcysteine 200mg/ml, injection, 10ml		Each	213,295
2	Adenosine 3mg/ml, injection, 2ml		Each	74,740
3	Adrenaline (Epinephrine) 0.15mg/0.3ml, auto-injection, 0.3ml		Each	5,570
4	Adrenaline (Epinephrine) 0.3mg/0.3ml, auto-injection, 0.3ml		Each	2,336
5	Adrenaline (Epinephrine) 1mg/ml, injection, 1ml		Each	7,520,710
6	Alfentanil 0.5mg/ml, injection, 2ml		Each	119,310
7	Alprostadil 0.5mg/ml, injection, 1ml		Each	6,250
8	Alteplase 50mg, 1 Vial		Each	7,960
9	Aminophylline 25mg/ml, injection, 10ml		Each	354,560
10	Amiodarone 50mg/ml, injection, 3ml		Each	223,660
11	Atracurium 10mg/ml, injection, 2.5ml		Each	81,270
12	Atracurium 10mg/ml, injection, 5ml		Each	58,400
13	Atropine 0.5mg/ml, injection, 1ml		Each	1,278,840
14	Atropine 1mg injection, 1ml		Each	2,353,110
15	Betamethasone 4mg/ml, injection, 1ml		Each	1,199,860
16	Biperiden 5mg, injection, 1ml		Each	63,180
17	Bupivacaine 5mg, Adrenaline 5mcg/ml, injection, 20ml		Each	292,780
18	Bupivacaine 5mg, Dextrose Anhydrous 72.7mg/ml, injection, 4ml		Each	974,370
19	Bupivacaine 5mg/ml injection, spinal, 4ml		Each	206,140
20	Bupivacaine 5mg/ml, injection, 10ml		Each	971,660
21	Caffeine 20mg/ml, injection, 1ml		Each	185,250
22	Calcium gluconate 10% m/v, injection, 10ml		Each	754,340
23	Cisatracurium 2mg/ml, injection, 2.5 ml		Each	266,650
24	Cisatracurium 2mg/ml, injection, 5ml		Each	237,390
25	Clonazepam 1mg/ml, injection, 1ml		Each	514,285
26	Clotiapine 10mg/ml, injection, 4ml		Each	78,395
27	Dantrolene 20mg, injection, 70 ml		Each	2,280
28	Desferrioxamine 500mg, injection		Each	49,970
29	Desmopressin 4mcg, injection, 1ml		Each	9,660
30	Dexamethasone 4mg, injection, 1ml		Each	5,270,300
31	Dexmedetomidine, 100 mcg/ml, Injection for infusion, 2ml		Each	58,320
32	Dextrose 50% m/v, injection, 20ml		Each	1,293,980
33	Dextrose 50% m/v, injection, 50ml		Each	1,140,740
34	Diazepam 5mg/ml, injection, 2ml		Each	771,330
35	Diclofenac 25mg/ml, injection, 3ml		Each	8,327,390
36	Digoxin 0,25mg/ml, injection, 2ml		Each	39,280
37	Dinoprost 5mg, injection, 1ml		Each	900
38	Dobutamine 12.5mg/ml, injection, 20ml		Each	206,440
39	Dopamine 40mg/ml, injection, 5ml		Each	106,755
40	Enoxaparin 40mg, injection, 0.4ml		Each	8,663,680
41	Enoxaparin 60mg, injection, 0.6ml		Each	901,800
42	Enoxaparin 80mg, injection, 0.8ml		Each	2,019,230
43	Ephedrine 50mg, injection, 1ml		Each	325,270
44	Ergometrine 0.5mg, injection, 1ml		Each	24,700
45	Erythropoietin 10 000 iu, injection, 0.6ml		Each	88,800
46	Erythropoietin 2 000 iu, injection, 0.3ml		Each	320,510
47	Erythropoietin 30 000 iu, injection, 0.6ml		Each	6,520
48	Erythropoietin 4 000 iu, injection, 0.3ml		Each	683,630

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
49	Erythropoietin 6 000 iu, injection, 0.3ml		Each	13,624
50	Etomidate 2mg/ml, injection, 10ml		Each	145,080
51	Fentanyl 0.05mg/ml, injection, 2ml		Each	1,581,570
52	Fentanyl 0.05mg/ml, injection, 10ml		Each	370,850
53	Fluorescein 100mg/ml, injection, 5ml		Each	1,536
54	Flupenthixol decanoate 20mg/ml, injection, 1ml		Each	1,507,530
55	Furosemide 10mg/ml, injection, 25ml		Each	245,280
56	Furosemide 10mg/ml, injection, 2ml		Each	7,085,900
57	Furosemide 10mg/ml, injection, 5ml		Each	342,230
58	Glucagon 1mg, injection, 1ml		Each	30,050
59	Glyceryl trinitrate 1mg/ml, injection, 10ml		Each	146,900
60	Glycopyrronium bromide 0.2mg/ml, injection, 2ml		Each	622,200
61	Haloperidol 10mg/ml, injection, 2ml		Each	24,220
62	Haloperidol 5mg/ml, injection, 1ml		Each	447,790
63	Heparin 1000 iu/ml, injection, 5ml		Each	693,310
64	Heparin 5000 iu/ml, injection, 5ml		Each	946,240
65	Hydrocortisone 100mg/2ml, injection, 2ml		Each	4,166,740
66	Hyoscine Butylbromide 20mg, injection, 1ml		Each	2,338,110
67	Insulin analogue, Human, Long-acting, 100 u/ml, disposable pen, 3ml		Each	33,860
68	Insulin analogue, Human, Ultrafast-acting 100 u/ml, disposable pen, 3ml		Each	229,559
69	Insulin analogue, Human, Ultrafast-acting 100 u/ml, vial, 10ml		Each	1,540
70	Insulin, Biosynthetic, Human, Isophane, 100 u/ml, disposable pen, 3ml		Each	2,832,200
71	Insulin, Biosynthetic, Human, Isophane, 100 u/ml, vial, 10ml		Each	903,640
72	Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, disposable pen, 3ml		Each	11,488,740
73	Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, penfilll cartridge for use in pens, 3ml (PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)		Each	2,188,000
74	Insulin, Biosynthetic, Human, Biphasic, 100 u/ml, soluble 30% and Isophane 70%, vial, 10ml		Each	4,520,360
75	Insulin, Biosynthetic, Human, Soluble, 100 u/ml, disposable pen, 3ml		Each	1,886,440
76	Insulin, Biosynthetic, Human, Soluble, 100 u/ml, vial, 10ml		Each	387,840
77	Iron dextran containing elemental iron 50mg/ml, injection, 10ml		Each	16,500
78	Iron dextran containing elemental iron 50mg/ml, injection, 2ml		Each	211,350
79	Iron sucrose containing elemental iron 20mg/ml, injection, 5ml		Each	271,550
80	Isulin analogue, Human, Ultrafast-acting 100 u/ml, penfill cartridge for use in pens, 3ml (PENS TO BE PROVIDED FREE OF CHARGE TO PATIENTS)		Each	7,725
81	Ketamine 10mg/ml, injection, 20ml		Each	96,930
82	Ketamine 100mg/ml, injection, 10ml		Each	61,060
83	Ketamine 50mg/ml, injection, 10ml		Each	87,050
84	Labetalol 5mg/ml, injection, 20ml		Each	193,390
85	Lidocaine 1% m/v, injection, not for iv use, 20ml		Each	1,821,100
86	Lidocaine 10% m/v, iv injection, 5ml		Each	39,220
87	Lidocaine 2% m/v injection, not for iv use, 20ml		Each	1,191,930
88	Lidocaine 2% m/v, Adrenaline 12.5mcg (1:80 000), dental cartridge, 1.8ml		Each	18,119,370
89	Lidocaine 2% m/v, dental cartridge, 1.8ml		Each	2,814,860
90	Lidocaine 2% m/v, iv injection, 5ml		Each	1,964,420
91	Lorazepam 4mg, injection, 1ml		Each	977,050
92	Magnesium sulfate 50%, injection, 2ml		Each	5,111,040
93	Mannitol 25% m/v, injection, 50ml		Each	19,320
94	Methylprednisolone 125mg, (as sodium succinate) injection, 2ml		Each	33,765

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
95	Methylprednisolone 40mg, (as sodium succinate) injection, 1ml		Each	5,160
96	Methylprednisolone 500mg, (as sodium succinate) injection, 8ml		Each	100,830
97	Methylprednisolone acetate 40mg/ml, injection, 2ml		Each	257,150
98	Methylprednisolone acetate 40mg/ml, injection, 5ml		Each	18,412
99	Metoclopramide 5mg/ml, injection, 2ml		Each	7,601,990
100	Midazolam 1mg/ml, injection, 5ml		Each	595,200
101	Midazolam 5mg/ml, injection, 10ml		Each	127,300
102	Midazolam 5mg/ml, injection, 3ml		Each	948,930
103	Morphine 10mg/ml, injection, 1ml		Each	3,307,110
104	Morphine 15mg/ml, injection, 1ml		Each	1,772,750
105	Naloxone 0.02mg/ml, injection, 2ml		Each	96,540
106	Naloxone 0.4mg/ml, injection, 1ml		Each	504,980
107	Natural Phospholipids (Poractant alpha), intra-tracheal solution, 120mg in 1.5ml, 1.5ml	Class 1	Each	35,215
108	Natural Phospholipids (Poractant alpha), intra-tracheal solution, 240mg in 3ml, 3ml	Class 2	Each	17,274
109	Needle, Insulin, 31G x 5mm, sterile, suitable for use with all prefilled insulin injection devices, 100		Each	82,770
110	Needle, Insulin, 31G x 8mm, sterile, suitable for use with all prefilled insulin injection devices, 100		Each	377,460
111	Neostigmine 0.5mg, injection, 1ml		Each	107,590
112	Neostigmine 2.5mg, injection, 1ml		Each	481,450
113	Octreotide 0.05mg, injection, 1ml		Each	14,020
114	Octreotide 0.1mg, injection, 1ml		Each	119,395
115	Octreotide 0.2mg/ml, injection, 5ml		Each	8,380
116	Oxytocin 10 iu, injection, 1ml		Each	6,406,260
117	Oxytocin 5 iu, injection, 1ml		Each	2,063,960
118	Oxytocin 5iu, Ergometrine 0.5mg, injection, 1ml		Each	538,290
119	Pantoprazole 40mg, injection, 10ml		Each	1,042,800
120	Paracetamol 10mg/ml, injection for IV infusion, 100ml		Each	1,585,240
121	Paracetamol 10mg/ml, injection for IV infusion, 50ml		Each	6,910
122	Pethidine 25mg/ml, injection, 1ml		Each	354,260
123	Pethidine 50mg/ml, injection, 1ml		Each	1,815,320
124	Pethidine 50mg/ml, injection, 2ml		Each	2,769,710
125	Phenylephrine 10mg, injection, 1ml		Each	637,460
126	Phenytoin 50mg/ml, injection, 5ml		Each	1,278,200
127	Phospholipids, Total (Beractant), 100mg/4ml, 1 Vial	Class 1	Each	35,215
128	Phospholipids, Total (Beractant), 200mg/8ml, 1 Vial	Class 2	Each	17,274
129	Potassium Chloride 15%, m/v injection, 10ml		Each	2,470,180
130	Potassium Phosphate Monobasic, Anhydrous, Potassium Phosphate Dibasic Anhydrous, 1.09g/1.05g, injection, 10ml		Each	131,090
131	Promethazine 25mg/ml, injection, 1ml		Each	691,430
132	Promethazine 25mg/ml, injection, 2ml		Each	319,811
133	Propofol 10mg/ml, injection, 20ml		Each	1,446,630
134	Propofol 10mg/ml, injection, 50ml		Each	195,590
135	Protamine 10mg/ml, injection, 5ml		Each	52,140
136	Quinine 300mg, injection, 1ml		Each	46,610
137	Ranitidine 25mg/ml, injection, 2ml		Each	822,410
138	Remifentanil 2mg, injection, 5ml		Each	47,070
139	Rocuronium 50mg, injection, 5ml		Each	777,100
140	Salbutamol 0.5mg, injection, 1ml		Each	301,240
141	Sodium bicarbonate 4% m/v, injection, 50ml		Each	109,550

Item No	Description	Therapeutic Class Numbers	Unit	Estimate
142	Sodium bicarbonate 8.5% m/v, injection, 50ml		Each	578,010
143	Sodium chloride 0.9% m/v, injection, 10ml		Each	12,400,540
144	Somatropin 15iu, powder for injection, cartridge + diluent		Each	23,720
145	Somatropin 30iu, powder for injection, cartridge + diluent		Each	24,895
146	Somatropin 36iu, powder for injection, cartridge + diluent		Each	426
147	Streptokinase 1.5MU injection		Each	10,155
148	Suxamethonium 50mg/ml, injection, 2ml		Each	635,010
149	Testosterone 1g injection, 1 injection		Each	16,415
150	Thiopentone 0.5g, injection, 20ml		Each	23,540
151	Tramadol 50mg/ml, injection, 2ml		Each	3,207,480
152	Tranexamic Acid 100mg/ml, injection, 5ml		Each	1,734,980
153	Vecuronium 4mg, injection, 2ml		Each	53,840
154	Verapamil HCl 2.5mg/ml, injection, 2ml		Each	17,910
155	Vitamin B Complex, injection, 10ml		Each	429,600
156	Vitamin B1 (Thiamine) 100mg/ml, injection, 10ml		Each	412,200
157	Vitamin B12 (Cyanocobalamin) 1000mcg, injection, 1ml		Each	487,350
158	Vitamin K1 (Phytomenadione) 10mg/1ml, injection		Each	773,990
159	Vitamin K1 (Phytomenadione) 2mg/0.2ml, injection		Each	3,500,390
160	Water for injection BP, injection, 10ml		Each	37,241,680
161	Water for injection BP, injection, 20ml		Each	4,112,500
162	Zuclopenthixol acetate 50mg, injection, 1ml		Each	228,680
163	Zuclopenthixol decanoate 200mg/ml, injection, 1ml		Each	2,142,750